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 Abstract 
The pharmaceutical industry is facing a period of drastic change in the way products are 
conceived and produced, due to the introduction of the Quality by Design (QbD) initiative put 
forth by the pharmaceutical regulatory agencies, such as the Food and Drug Administration 
(FDA) and the European Medicines Agency (EMA). A key concept introduced in the QbD 
framework is that of design space (DS) of a new pharmaceutical product, defined as “the 
multidimensional combination and interaction of raw material properties and process 
parameters that have been demonstrated to provide assurance of quality” for the final product. 
Once the DS has been approved by the regulatory agency, the process can be run within the 
DS without any further regulatory approval, thus significantly increasing process flexibility 
and allowing pharmaceutical companies to continuously optimize the operation of their 
processes. 
Bayesian modelling techniques (such as Bayesian multivariate linear regression and joint 
Bayesian/latent variable modelling) have recently proved to play a key role for the 
quantification of “assurance” of quality advocated by the regulatory agencies. With these 
techniques, the different sources of uncertainty (parametric; structural; measurement 
uncertainty in the calibration dataset) that affect the DS prediction can be handled in a unified 
framework, and the “assurance” of quality can be quantified as the probability that the product 
under development will meet its specifications. However, the methodologies that are currently 
available in the literature primarily focus on the incorporation of parametric and structural 
uncertainty in the Bayesian framework, while systematic approaches for the incorporation of 
measurement uncertainty are still missing. 
The aim of this Thesis is to propose a systematic approach for the incorporation of 
measurement uncertainty in the Bayesian identification of the DS of a new pharmaceutical 
product. Specifically, the proposed approach extends a joint Bayesian/latent variable 
methodology for DS identification recently proposed by Bano et al. (2018). A step-by-step 
methodology is proposed to handle measurement uncertainty in the calibration dataset, and 
three case studies (two of which involving experimental data of pharmaceutical granulation) 
are used to test its performance. The results show that the incorporation of measurement 
uncertainty can, under certain circumstances, significantly affect the prediction of the DS. 
  
  
Riassunto 
 
 
Con l’introduzione del concetto di Quality-by-Design i vari enti regolatori internazionali hanno 
di fatto dato inizio ad una rivoluzione nel modo nel quale le aziende farmaceutiche si devono 
approcciare al processo di produzione e di sviluppo di un prodotto medicale. Questa proposta 
di cambiamento sistematico è avvenuta in un momento topico; le industrie infatti vedevano la 
profittabilità dei loro investimenti diminuire mentre i costi dovuti agli errori di produzione 
continuavano ad aumentare (Abboud and Hensley, 2003). In questa nuova modalità di sviluppo 
ed operazione dei processi i punti focali dovranno essere la conoscenza approfondita del 
processo e le decisioni basate su dati scientifici, non sarà più accettabile un approccio basato 
sull’esperienza dove l’effettiva qualità di un prodotto farmaceutico è testata a campione tra i 
prodotti finiti. Tra gli altri si aggiunge infatti anche la necessità che la qualità finale di un 
prodotto sia inserita tra i parametri di sviluppo ed assicurata fin dalla concezione del prodotto 
e del suo processo produttivo. Oltre agli ovvi benefici al consumatore finale anche le stesse 
aziende farmaceutiche possono trarre vantaggio da questa iniziativa, infatti un controllo 
integrato, unito ad una approfondita conoscenza del processo ed alla possiblità di non fallire 
alcun batch portano benefici economici interessanti. Ai benefici economici si sommano anche 
degli sgravi regolatori che permettono al processo di essere condotto in modo ottimale senza 
essere costretti a seguire la ricetta che è stata approvata. Quest’utimo beneficio è legato al 
concetto di spazio di progetto (design space), spazio multivariato delle variabili di progetto ed 
operative e della loro relazione, che permette di assicurare l’ottenimento di una qualità 
richiesta. Un movimento dei parametri operativi all’interno delle configurazioni delimitate 
dallo spazio di progetto non consiste, nel Quality-by-Design, in un cambiamento del processo 
produttivo e di conseguenza non richiede autorizzazioni aggiuntive; un vantaggio per l’azienda 
come detto, ma anche per l’ente regolatore. La determinazione di uno spazio di progetto deve 
avvenire con l’ausilio di modelli atti a rappresentare il processo in corso senza dimenticare 
l’interconnessione tra i parametri operativi e la loro influenza gli uni sugli altri. Uno dei punti 
chiave nel concetto di spazio di progetto è il fatto che lo spazio di progetto dovrebbe indicare 
i punti che danno una certa assicurazione di qualità come appartenenti al suddetto, e quindi 
come condizioni operative e proprietà delle materie prime che possono essere usate nella 
conduzione del processo. Il fulcro, a parità di validità, deve essere l’effettiva capacità di un 
metodo per la definizione dello spazio di progetto di dare o meno un effettiva assicurazione 
della qualità, non solo un indicazione qualitativa. È in questo frangente che i metodi statistici 
di impostazione Bayesiana si sono rivelati più efficaci. L’obiettivo di questa Tesi è incorporare 
in una metodologia Bayiesiana per l’identificazione di uno spazio di progetto un ulteriore fonte 
di incertezza, finora non esplorata in questo frangente: l’incertezza dovuta all’errore di misura. 
 Al fine del conseguimento di questo obiettivo viene illustrata una metodologia che integra 
quella porposta in un recente articolo di Bano et al., (2018). 
La Tesi è strutturata in questo modo. Nel Capitolo 1 è presente una trattazione generale del 
nuovo approccio proposto dagli enti regolatori con definizione dei termini chiave e delle 
principali sfide ancora aperte. Nel Capitolo 2 è sono discussi i metodi matematici che sono stati 
usati per l’ottenimento dei risultati conseguiti o durante le analisi preliminari. Il Capitolo 3 
mostra come i metodi matematici sono stati applicati per la definizione di uno spazio di 
progetto, e come uno spazio di progetto Bayesiano sia in grado di dare l’assicurazione di qualità 
alla base della ricerca in oggetto, oltre a mostrare la metodologia che il presente lavoro espande. 
Nel Capitolo 4 il problema dell’errore di misura viene trattato più approfonditamente. Cosa 
comporta, che fonti ha ed infine come viene affrontato nella metodologia proposta. Nello stesso 
capitolo è inoltre presentata la metodologia per l’incorporazione dell’errore di misura nella 
determinazione di uno spazio di progetto Bayesiano per un nuovo prodotto farmaceutico, 
assieme ad un esempio nel corso del quale la metodologia viene sviscierata e spiegata. Il 
Capitolo 5 presenta alcuni dei risultati ottenuti mettendo ogni volta in luce come i risultati sono 
ottenuti e sottolineando il corretto metodo di azione nell’applicazione della metodologia. Una 
breve conclusione chiude il documento con delle considerazioni finali sulla metodologia e sulle 
direzione di indagine possibili per ulteriori approfondimenti sull’argomento. 
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Introduction 
 
In 2004, the ICH released a set of guidelines in its Q8 (R2) document, adopted in 2006 by the 
Food and Drugs Administration (FDA) and the European Medicine Agency (EMA), stressing 
the importance of a Quality by Design (QbD) approach in the pharmaceutical industry. 
In the guideline, QbD is described as “a systematic approach to development that begins with 
predefined objectives and emphasises product and process understanding and process control, 
based on sound science and quality risk management” (ICH, 2009). 
The adoption of the QbD framework in the pharmaceutical context requires a paradigm shift 
from the traditional Quality by Testing (QbT) approach, where product quality is tested and 
assessed at the end of the production process, to an enhanced one, based on scientific 
knowledge, where quality is “built” into the final product since its original conception. 
The practical implementation of QbD in the pharmaceutical industry requires the adoption of 
novel modelling approaches to pharmaceutical product development. Specifically, 
mathematical modelling is required in order to link the desired critical quality attributes 
(CQAs) of the final product with the critical process parameters (CPPs) and raw material 
properties of the process exploited for the production of the desired product. CQA are defined 
as “physical, chemical, biological, or microbiological properties or characteristics that should 
be within an appropriate limit, range, or distribution to ensure the desired product quality” 
(ICH, 2009). On the other hand, CPPs are defined as “process parameters whose variability has 
an impact on a critical quality attribute and therefore should be monitored or controlled to 
ensure the process produces the desired quality” (ICH, 2009). Once a mathematical model 
(data-driven or semi-empirical or first-principles) is obtained in order to link the CPPs and raw 
material properties to the product CQAs, the so-called design space (DS) of the pharmaceutical 
product can be obtained. The DS is defined as “the multidimensional combination and 
interaction of input variables (e.g., material attributes) and process parameters that have been 
demonstrated to provide assurance of quality” (ICH, 2009). The identification of the DS has 
several key benefits, many of which stem from the fact that as long as the CPPs and raw 
materials proprieties are changed inside the boundaries set by the approved DS, regulatory 
post-approval change procedures are not needed. From the perspective of a pharmaceutical 
company, this represents a competitive advantage since the process can be run (and therefore 
its operation can be optimized) within the DS without initiating any regulatory post-approval 
procedure. 
The concept of “assurance” of quality contained in the regulatory definition of DS requires the 
quantification by the manufacturer of the reliability of the proposed design Space (Peterson, 
 2008). Several studies (Stockdale and Cheng, 2009; Peterson and Lief, 2010; Debrus et al., 
2011; Peterson et al., 2017) demonstrated the ability of Bayesian methodologies to give a 
rigorous scientific metric (i.e. the probability that the product will meet its specifications) in 
order to scientifically quantify the concept of “assurance” of quality. The advantage of these 
methodologies is that different sources of uncertainty (parametric, structural, measurement 
uncertainty in the calibration dataset) can be incorporated in a unified framework and can 
therefore be treated in a straightforward fashion. However, while all the studies available in the 
literature on Bayesian DS determination focus on parameteric and structural uncertainties, 
reliable methodologies to include measurement uncertainty in the Bayesian framework are still 
missing. 
The aim of this Dissertation is to present a possible way to include this source of uncertainty 
in Bayesian DS identification exercise. Specifically, we show how measurement uncertainty 
can be included in the Bayesian DS determination methodology recently proposed by Bano et 
al., (2018). The proposed approach has been tested on three case studies. The first is a highly 
correlated mathematical case study. The second and the third are derived from industrial or 
experimental practice and regards granulation processes. The second one uses historical data 
to establish the design space of a roll compaction dry granulation, the third one for a high shear 
wet granulation.  
The Dissertation is divided into five chapters. In the first chapter, the Quality by Design 
initiative is explained in depth, and the fundamental concepts and terms are explained. In the 
second chapter, background on some of the principal mathematical tools used in this work is 
presented. In the third chapter, state of the art in the probabilistic techniques for the 
determination of a design space is reported along with the Bayesian/Latent variable approach 
(Bano et al., 2018) methodology. In the fourth chapter, a contextualization on the measurement 
error is presented, and the methodology to include the added uncertainty in the design space 
determination exercise is reported. In the fifth chapter, three case studies are shown supporting 
and explaining the methodology. Some final remarks and possible direction for future studies 
will conclude the thesis.  
  
 
  
  
Chapter 1 
Motivation and state of the art  
 
In this Chapter, an overview of the Quality by Design (QbD) initiative that has recently been 
put forth by the pharmaceutical regulatory agencies will be given, with particular focus to its 
implications for the analyses proposed in the Dissertation.  
1.1 Quality by Design 
Although it is perceived as cutting edge for its societal impact, the pharmaceutical industry has 
been known to rely on outdated techniques in product development and manufacture (Tomba , 
2013). Product quality and performance were achieved by restricting flexibility in the 
manufacturing process and by random end-product testing (Yu, 2008). In 2004, the 
International Conference on Harmonisation of technical requirements for registration of 
pharmaceuticals for human use (ICH) released a set of guidelines in its Q8 document, adopted 
in 2006 by the Food and Drugs Administration (FDA) and the European Medicine Agency 
(EMA), stressing the need of a different approach in pharmaceutical product design and 
manufacturing. The issue was not only the inability to quantify the assurance of achievement 
of the required level of quality, but the cost of inefficiencies linked to the methods in use. In a 
survey on the state of the pharmaceutical industry. In 2003, the Wall Street Journal in an article 
from Abboud and Hensley, quantified the percentage of product that failed to pass the desired 
quality threshold due to manufacturing shortcomings between the 5% and 10% of the produced 
medicines. To give an additional measure of the manufacturing deficiencies impact on the 
industry, the number of recalled medicines and the manufacturing expenses linked to those 
percentages of recall were reported in the article; both increased yearly. In 2002, the FDA 
counted 354 prescription-drugs recall, up from 248 in 2001, and the linked manufacturing 
expenses accounted to the 36% of the industry total, more than double what at the time was 
devoted to research and development (Abboud and Hensley, 2003). The proposal of this change 
happened at a pivotal time. Many patents on high profitable drugs were approaching, or had 
already passed, expiration date and development of new molecules to substitute them was 
lagging. In 2005, the FDA approved 18 new molecules, compared to the 31 of 2000 and to the 
53 of 1996 (Hughes, 2009). In these circumstances, the regulatory agencies prompted a new 
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approach to product development and manufacturing introducing the concept of Quality by 
Design (QbD).  Taking inspiration from other industrial fields the quality by design initiative 
focuses on the promotion of robust, systematic, science based tools rather than fixed traditional 
procedures based on experience and custom. 
According to the Quality by Design paradigm, in contrast to previous Quality by Testing 
approach, quality must be built into the end-product from its design rather than being evaluated 
at the end of the manufacturing process. This is cemented in the definition of QbD given in the 
ICH guidelines as “a systematic approach to pharmaceutical development that begins with 
predefined objectives and emphasizes product and process understanding based on sound 
science and quality risk management” (ICH, 2009). 
In order to inspire a practical implementation of the QbD initiative, a number of different 
elements and criteria must be identified and defined. First, it is necessary to define what 
“quality” is. ICH defines quality as the suitability of a drug substance or drug product for its 
Figure 1.1 Comparison between two simplified quality assurance diagrams 
for generic drugs; the upper one refers to the Quality by Testing methodology, 
the lower one to the Quality by Design one. (Adapted from Yu, 2008) 
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intended use. This term includes such attributes as the identity, strength, and purity (ICH, 
1999).  With this definition in mind, it is possible to introduce the concept of criticality. The 
concept of criticality can be used to describe any feature or material attribute, property or 
characteristic of a drug substance, component, raw material, drug product or device, or any 
process attribute, parameter, condition or factor in the manufacture of a drug product (Garcia 
et al, 2008). The assessment of a parameter as critical or non-critical is a crucial step of a risk-
based approach and leads to the identification of a Quality Target Product Profile (QTPP) for 
the product under development Critical Quality Attributes (CQAs) and Critical Process 
Parameters (CPPs).  
1.2 Quality by design: terminology 
In the following, the main terminology adopted in the Quality by Design framework is briefly 
summarized. 
1.2.1 Quality Target Product Profile (QTTP) 
QTPP is defined as a prospective summary of the quality characteristics of a drug product that 
ideally will be achieved to ensure the desired quality, taking into account safety and efficacy 
(ICH, 2009). In other words, QTPP are attributes of the desired drug, based on intended use, 
method of administration, pharmacokinetic mechanisms and so on. Examples of QTPP are, for 
instance, dosage form and strength, physical qualities such as odour, shape and uniformity, 
stability or even container closure system, to cite a few (Sun, 2010).  
Once defined the QTPP, it is possible to conduct a risk assessment based on data and process 
knowledge to determine the criticality of what influences the process based on cause and effect 
relationships, relative to probability, severity, detectability, and sensitivity. Probability is the 
likelihood of deviation from QTPP, while severity is the entity of the aforementioned deviation. 
Detectability refers to the ability to discover or determine the existence, presence, or fact of 
this deviation and sensitivity is the attenuation of interactions between multivariate dimensions 
(Garcia et al, 2008). With this risk-based assessment, it is possible to define Critical Quality 
Attributes (CQAs) and Critical Process Parameters (CPPs). 
1.2.2 Critical Quality Attributes (CQAs) and Critical Process Parameters 
(CPPs) 
A CQA is defined as a physical, chemical, biological or microbiological property or 
characteristic that should be within an appropriate limit, range, or distribution to ensure the 
desired product quality (ICH, 2009). Examples of CQAs are for instance the Content 
Uniformity of the least concentrated Active Pharmaceutical ingredient (API) in a fixed-dose 
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combined instant release medicinal capsule or API Dissolution, linked to tablet density, in an 
extended release coated medicinal capsule (Maguire and Peng, 2015). 
A CPP is defined as a process parameter whose variability has an impact on a critical quality 
attribute and therefore should be monitored or controlled to ensure the process produces the 
desired quality (ICH, 2009). Examples of CPP are for instance the number of blender 
revolution in a blending process or the screen opening size in a screening milling process 
(Maguire and Peng, 2015). It is important to note that CQAs and CPPs can evolve throughout 
the product lifecycle, from the initial development through marketing and until the product 
discontinuation (ICH, 2009) as more data and a deeper understanding of process become 
available to update the criticality assessment. 
1.2.3 Design space (DS) 
The concept of design space is one of the key definitions on which the QbD framework is 
based, and its description is expected to be one of the results of the pharmaceutical development 
investigation (Tomba , 2013). The ICH definition of design space is: “the multidimensional 
combination and interaction of input variables (e.g., material attributes) and process parameters 
that have been demonstrated to provide assurance of quality” (ICH, 2009). 
With the previous QbT, paradigm manufacturers were not permitted to make changes to 
operating parameters or other process change without filing Chemistry, Manufacturing and 
Controls (CMC) supplements as part of the post-approval change process. As a result the 
regulatory agencies were overwhelmed by post-approval changes requests, for example in 2005 
and 2006 FDA Office of Generic Drugs received over 3000 post-approval changes requests 
annually (Yu, 2008).  
The QbT approach placed little or no emphasis on a properly designed process, one that is both 
efficient and effective can ensure product quality. Furthermore, the regulatory process with its 
cumbersome requirements to assure strict adherence to the experience-based design, proved in 
the end to be pyrrhic since it inhibited continuous improvement and real time assurance of 
quality (Yu, 2008). In contrast with the QbT paradigm, QbD and the introduction of the concept 
of design space drastically changed the classical way agencies used to supervise 
pharmaceutical development. Movements inside the design space are not considered as a 
change and are not undergo a regulatory post-approval procedure. 
The design space is considered the ultimate result of the manufacturing process understanding 
in the development of a new product, due to the necessity of identifying all critical process 
parameters and critical quality attributes of the feed and of the product. Since it is needed to 
predict a working zone that quantifies in some way the assurance of quality, the ability to 
predict, based on historical data and similar production campaign, is honed throughout the 
product lifecycle and as more data becomes available, culminating as the knowledge of the 
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process become complete. According to FDA, a process is considered well understood when 
(FDA, 2004): 
• all critical sources of variability are identified and explained;  
• variability is managed by the process;  
• product quality attributed can be accurately and reliably predicted over the design space 
established for materials used, process parameters, manufacturing environmental and 
other conditions. The ability to predict reflects a higher degree of process 
understanding.  
The ICH pharmaceutical development Q8 document provides a general guideline on how to 
construct and present a Design Space, without setting a precise methodology, but leaving the 
initiative to the company to select the most appropriate methods and tools. 
While not stated explicitly in the first draft of the document, the second revision of the 
pharmaceutical development Q8 (R2) document specifies that the multivariate nature of the 
Design Space, as per its definition, must be taken into account. It is important not only to select 
the CCPs and CQAs with care but also to measure their interaction with one another and with 
other parameters or quality attributes that could surpass the edge of criticality and become 
relevant if not critical to the process. For this reason, a design space cannot be expressed as a 
combination of proven acceptable ranges, namely ranges of the process parameters, obtained 
for each single parameter while keeping the other constant, for which the operation resulted in 
producing a product meeting the relevant quality criteria. In accordance to the general spirit of 
the QbD initiative, the regulatory agencies left the companies the possibility of choice on how 
to establish and present Design Spaces as long as all choices made in it are correctly justified 
and explained. Design Spaces could be presented for the single units or a single design spaces 
could be established for multiple operations up to the whole production line. For example, in 
the case of a drug product that undergoes degradation in solution before lyophilisation, the 
design space to control the extent of degradation (e.g., concentration, time, temperature) could 
be expressed for each unit operation or as a sum over all unit operations (ICH, 2009). The same 
spirit applies to multiple-scale spanning design Spaces. It is necessary for the company to 
provide data on scale-relevance of the various CQAs and CPPs, along with the specification 
on which scale the data at the base of the design Space were collected. In this case 
dimensionless numbers and/or models for scaling can be included as part of the design space 
description (ICH, 2009). 
1.2.4 Process Analytical Technology (PAT) 
The Process Analytical Technology (PAT) framework is defined by FDA as “a system for 
designing, analysing and controlling manufacturing through timely measurements (i.e., during 
processing) of critical quality and performance attributes of raw and in-process materials and 
processes, with the goal of ensuring product quality”. It is important to note that the term 
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analytical in PAT is viewed broadly to include chemical, physical, microbiological, 
mathematical, and risk analysis conducted in an integrated manner. The goal of PAT is to give 
tools and principles to enhance understanding and control of the manufacturing process (FDA, 
2004) ; these tools are then used for clarification via scientific study of the problems 
encountered in product and process development. In the PAT framework, these tools can be 
categorized according to the following (FDA, 2004): 
 Multivariate tools for design, data acquisition and analysis,  
 Process analysers, 
 Process control tools,  
 Continuous improvement and knowledge management tools. 
Multivariate tools include all the multivariate mathematical techniques including, for example, 
latent variable modelling and Bayesian statistical analysis, applied to the scientific 
understanding of the relevant multifactorial relationship between inputs and outputs of a 
specific process and their generalization to a broader class of processes. 
Process analysers are all the tools used to collect process data. These measurements can be 
obtained by removing, isolating and analysing the sample in proximity to the process stream, 
by diverting the sample from the manufacturing process and returning it to the process stream 
after the measurement or by keeping the sample inside the process stream, where the 
measurement can be made invasive or not. Process analysers usually produce a massive amount 
of data, and dedicated multivariate analysis techniques must be applied to render them usable.  
Process control tools are intended to monitor the state of a process and actively manipulate it 
to maintain the desired trend. Strategies should accommodate the attributes of input materials, 
the ability and reliability of process analysers to measure critical attributes, and the 
achievement of process endpoints to ensure consistent quality of the output materials and the 
final product (FDA, 2004). 
The results of the application of the PAT framework is the availability of a large amount of 
data, from which comprehensive models can be derived, either from first principles - if the 
process knowledge is mature enough - through empirical modelling or a combination of the 
two. Since their origin is found in the application of PAT frameworks, models are part of the 
framework too, and as such are PAT tools themselves. 
 
1.2.5 Control strategy 
To maintain a process inside the boundaries defined by its design space, thus ensuring that a 
product of required quality will be produced consistently, it is necessary to employ an efficient 
control strategy. It should be noted that the term control does not usually refer to the traditional 
engineering understanding of process control. A control strategy is defined by the ICH in its 
pharmaceutical development Q8 (R2) document as a planned set of controls, derived from 
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current product and process understanding that ensures process performance and product 
quality. The controls can include parameters and attributes related to drug substance and drug 
product materials and components, facility and equipment operating conditions, in-process 
controls, finished product specifications, and the associated methods and frequency of 
monitoring and control. The elements of the control strategy should describe and justify how 
in-process controls of the CPPs and the controls of input materials, intermediates and drug 
products CQAs contribute to the final product quality (ICH, 2009).  
Understanding sources of variability and their impact on downstream processes or processing, 
in-process materials, and drug product quality can provide an opportunity to shift controls 
upstream and minimise the need for end-product testing. The goal is to design adaptive process 
steps and appropriate control strategy to ensure that the variability can be addressed in an 
adaptable way to deliver consistent product quality. This process would an alternative 
manufacturing paradigm where the input variability could be less tightly constrained.  
Enhanced understanding of product performance and appropriate variability control can justify 
the use of alternative approaches to determine that the material is meeting its CQAs. The use 
of such alternatives could support real time release testing.  
The ICH in its pharmaceutical development Q8 (R2) document reports a few examples. For 
instance, disintegration that could serve as a surrogate for dissolution for fast-disintegrating 
solid forms with highly soluble drug substances. Another example is the unit dose uniformity 
performed in-process (e.g., using weight variation coupled with near infrared (NIR) assay) can 
enable real time release testing and provide an increased level of quality assurance compared 
to the traditional end product testing. From this point of view by assuring continuous quality, 
real time release testing could supplant the time intensive end product testing. 
In summary, a control strategy can include, but it is not limited to, the following (ICH, 2009): 
• Control of input material attributes (e.g. APIs, excipients, primary packaging 
materials), based on understating of their impact on processability or product quality;  
• Product specification(s);  
• Controls for unit operations that have an impact on downstream processing or product 
quality;  
• In-process or real-time release testing in lieu of end-product testing;  
• A monitoring program for verifying prediction models performances (e.g. through full 
product testing at regular intervals).  
When establishing and submitting a control strategy, companies are not limited on the type of 
approach they have to take. For example a control step could use an end product testing 
approach and another could use real time release testing. What is required though is to explain 
and justify the selection of one strategy over another.  
As with the design space, also the control strategy should be honed throughout the lifecycle of 
the product, as new data are collected and analysed and more knowledge is obtained. With this 
 
10 Chapter 1 
 
goal in mind continuous process verification tools should be employed. Continuous process 
verification is an approach to process validation that includes the continuous monitoring and 
evaluation of manufacturing process performance (ICH, 2009). Examples of this process 
verification made by the ICH are for instance trend analysis of a manufacturing process as 
additional experience is gained during routine manufacture. Continuous process verification 
can utilize in-line, on-line or at-line monitoring or controls to evaluate process performance, 
and can enhance the evaluation of the manufacturing process if it provides substantially more 
information on process variability and control. The advantage of using continuous process 
verification is that it provides the foundation for a robust process performance and product 
quality monitoring system, increasing in the meanwhile product and process knowledge and 
facilitation of continual improvement opportunities for process and product quality. This in 
turn fosters an increased confidence in the applied control strategy and the process design 
space, since they are continuously controlled, improved and verified. 
1.3 Benefits of QbD Implementation  
The QbD initiative provides an enhanced approach to pharmaceutical development and 
manufacturing, based on scientific and engineering principles for assessing and mitigating risks 
of production shortcomings, with the underlying goal of enhancing the quality of the drug 
products. The goal of pharmaceutical development with QbD is to achieve a near complete 
understanding of the scientific aspects of the process. The level of actual knowledge achieved 
is based on well-designed drug formulation and manufacturing efficacy and efficiency. In 
pharmaceutical manufacturing, the goal of QbD is to provide systems able to assure quality in 
real time and to identify and address disturbances entering the process. This endeavour is 
certainly simplified by using appropriate experimental design (DOE) methods and multivariate 
statistical analysis techniques to deepen the process knowledge.   
In Table 1.1, a comparison between the QbT and the QbD approaches. The increased degree 
of importance of data and process knowledge is evident in the shift of the focus from an 
empirical, experience-based one, to a science-based one, where the ability to infer relations, in 
absence of the true mechanistic models, in crucial to the compliance.  
This QbD approach has a monetary value not directly derived from the regulatory relief that 
comes from the design space and control strategy, but also from the opportunity for an early 
optimization of the manufactured drug product. 
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Table 1.1. Comparison between QbT-based and QbD-based approaches to 
the pharmaceutical development and manufacturing, adapted from (ICH, 
2009) 
Aspect QbT-based approach QbD-based approach 
Pharmaceutical development − Empirical 
− Typically univariate experiments 
 
− Systematic, relating mechanistic 
understanding of material CQAs and 
CPPs to product CQAs 
− Multivariate experiments 
− Establishment of design space 
 
Manufacturing process − Fixed 
− Validation based on initial full-
scale batches 
− Focus on optimization and 
reproducibility 
 
− Adjustable within design space 
− Lifecycle approach to validation 
− Focus on control strategy and 
robustness 
− Use of statistical process control 
 
Process control − In-process tests for go/no go 
decisions 
− Off-line analysis 
 
− Process analytical tools utilized 
with appropriate feedforward and 
feedback control strategies 
− Process operations tracked and 
trended to support continual 
improvement 
 
Product specifications − Primary means of quality control 
− Based on batch data available 
 
− Part of the overall quality control 
strategy 
− Based on desired product 
performance (safety and efficacy) 
 
Control strategy − Drug product quality controlled 
mainly by intermediate and end 
product testing 
 
− Drug product quality ensured by 
risk-based control strategy 
− Quality controls shifted upstream, 
with the possibility of real time 
release 
 
Lifecycle management − Reactive (i.e., problem solving 
and corrective action) 
 
− Proactive action 
− Continual improvement facilitated 
 
 
In Fig. 1.2 the trend of total revenues of a total product are reported, from the discovery to the 
expiration of the patent. The solid line represents a product developed with the QbT paradigm, 
while the dashed line represents a product developed with the QbD best practices. In the pre-
launch phase a lot of monetary investment have to be made in order to finance the necessary 
testing phase that usually lasts around ten years after which the product is launched and the 
sales start to increase revenue. 
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Sales continues to rise afterwards and after around ten other years a peak of revenue is 
achieved. After that sales could decline or continue to be relevant. More often than not products 
are set to launch well before the manufacturing process is optimized. IBM estimated that 
improving a new product and process development with science and risk based analysis and 
continuous improvement of the process, using strictly speaking a QbD-approach, could help 
reducing the period to launch to peak by as much as five years. This gives the product an 
enormous amount of added value. As an example, a drug with peak annual sales of US$1 billion 
was estimated to generate an extra US$1.6 billion over its lifetime (IBM Business Consulting 
Services, 2005). 
Another useful guideline to implement and obtain a QbD approach is the one described in ICH 
Q10 “Pharmaceutical Quality System” (PQS). The PQS is a model for an effective quality 
management system for the pharmaceutical industry that is based on International Standards 
Organisation (ISO) quality concepts, includes applicable Good Manufacturing Practice (GMP) 
regulations and complements ICH Q8 “Pharmaceutical Development” (ICH, 2008). ICH Q10 
demonstrates industry and regulatory authorities’ support of an effective pharmaceutical 
quality system to enhance the quality and availability of medicines around the world in the 
interest of public health. Implementation of ICH Q10 should facilitate innovation and continual 
improvement and strengthen the link between pharmaceutical development and manufacturing 
activities.  
Figure 1.2: Comparison of revenue trends for a drug product during its lifetime if a QbT 
(solid line) or a QbD (dashed line) approach were used for development and manufacturing 
(IBM Business Consulting Services, 2005). 
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Table 1.2: potential opportunity to enhance science and risk based regulatory 
approaches, from ICH Q10 (ICH, 2008)  
Scenario Potential Opportunity 
1. Comply with Good Manufacturing Practices Compliance – status quo 
2. Demonstrate effective pharmaceutical quality 
system, including effective use of quality risk-
management principles (e.g., ICH Q9 and ICH Q10). 
Opportunity to: increase use of risk based approaches 
for regulatory inspections. 
3. Demonstrate product and process understanding, 
including effective use of quality risk-management 
principles (e.g., ICH Q8 and ICH Q9). 
Opportunity to: facilitate science based 
pharmaceutical quality assessment; enable innovative 
approaches to process validation; establish real-time 
release mechanisms. 
4. Demonstrate effective pharmaceutical quality 
system and product and process understanding, 
including the use of quality risk management 
principles (e.g., ICH Q8, ICH Q9 and ICH Q10). 
Opportunity to: increase use of risk based approaches 
for regulatory inspections; facilitate science based 
pharmaceutical quality assessment; optimise science 
and risk based post-approval change processes to 
maximise benefits from innovation and continual 
improvement; enable innovative approaches to 
process validation; establish real-time release 
mechanisms. 
 
In Table 1.2, a prospect of the potential opportunity to enhance science and risk based 
regulatory approaches obtainable by implementing the ICH Q10 Pharmaceutical Quality 
System. The implementation of Q10 means the achievement of three main objectives, achieve 
product realisation, establish and maintain a state of control, and facilitate continual 
improvement. Product realization is defined as “Achievement of a product with the quality 
attributes appropriate to meet the needs of patients, health care professionals, and regulatory 
authorities (including compliance with marketing authorisation) and internal customers’ 
requirements.” (ICH, 2008). This is done through the implementation of a QbD logic and the 
use of a well-maintained and derived design space. Establishing and maintaining a state of 
control means using quality risk management and an optimal control strategy providing 
assurance of continued suitability and capability of processes. Facilitate continual 
improvement means keeping in place continuous process verification, among other systems, to 
identify and implement appropriate product and process improvements thereby increasing the 
ability to fulfil quality needs consistently. 
It is also necessary to stress the importance of a model-based approach to the establishment of 
the design space. Model-based design spaces maintain all the benefits of submitting a design 
space, such as more freedom of selection of the process parameter while providing some 
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powerful tools to conduct different analysis. A data driven and model driven design space can 
be used to limit the portion of the process knowledge space in which experiments to determine 
the optimal operating conditions are needed, greatly simplifying the ensuing experimental 
design. Another use in which the design space of the process can be helpful is online fault 
detection. The design space can be used to develop an accurate detection chart as it embodies 
process understanding and can be easily used to ensure that it is working as anticipated to 
deliver product quality attributes as predicted by the design space. This monitoring could 
include trend analysis of the manufacturing process as additional experience is gained during 
routine manufacture. Even the perceived deficiency of the model based approach, that is the 
need of periodic maintenance, can be seen as an opportunity to deepen the knowledge of the 
process that is, as mentioned above, crucial in the compliance to the QbD initiative. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Chapter 2 
Mathematical Background 
 
In this chapter, the basis of the main mathematical techniques employed in this work are 
presented, starting from the description of two dimensional reduction techniques, Principal 
Components Analysis (PCA) and Partial Least Squares (PLS) and then continuing with an 
overview on Bayesian statistics. 
2.1 Principal Component Analysis 
Let let 𝐗[𝐼 × 𝐽] be a historical dataset composed of I rows and J columns. Rows correspond to 
samples, while columns correspond to variables. PCA is a statistical tool that allows describing 
the historical dataset by means of few variables, called latent variables, that describe the 
maximum multidimensional variance of the historical dataset.  The notable advantage is that, 
in the presence of strong collinarity in the original dataset, the number of latent variables is 
much smaller than the number of original input variables. 
PCA employs an eigenvector decomposition of the covariance matrix of the data. 
The covariance of X is equal to: 
cov(𝐗) =  𝐗
౐𝐗
ூି𝟏
.                  (2.1)  
Eigenvector of the covariance matrix are calculated according to: 
cov(𝐗)𝐩௡ = 𝛌௡𝐩௡                 (2.2)  
For each eigenvector p the corresponding vector t is found as: 
𝐗𝐩௡ = 𝐭௡ .                 (2.3)  
And can be used to write the original X matrix as the sum of the outer products of the tp pairs: 
𝐗 = 𝐭ଵ𝐩ଵ୘ + 𝐭ଶ𝐩ଶ୘ + 𝐭ଷ𝐩ଷ୘ + ⋯ + 𝐭ே𝐩ே୘ + 𝐄 ,                     (2.4) 
where N is a number no greater than the smaller dimension of X, i.e: N ≤ min(I,J); tn are the 
model scores; pn are the model loadings; E is the matrix of the residuals. The scores are 
orthogonal, and convey information on how samples relate to each other, while the loadings 
are orthonormal if X is autoscaled, otherwise they are orthogonal, and convey information on 
how variables are correlated with each other.  
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The model scores tn are collected in the score matrix 𝐓, while the model loadings are collected 
in the loading matrix 𝐏. 
The decomposition of the historical dataset can be reformulated as the following optimisation 
problem:  
  max (𝐏
୘𝐗୘𝐗𝐏)  
s. t.   𝐏୘𝐏 = 1    
                  (2.5) 
By applying the method of Lagrange multipliers, Equation (2.5) can be rewritten as: 
L(𝐏) = (𝐏୘𝐗୘𝐗𝐏 − λ(𝐏୘𝐏 − 1)) .                  (2.6) 
According to Lagrange multipliers method Equation (2.6) has to be derived by P and λ and the 
resulting equations have to be set to zero: 
ୢ୐(𝐏)
ୢ𝐏
ቀ𝐏୘𝐗୘𝐗𝐏 − 𝜆(𝐏୘𝐏 − 1)ቁ = 𝐏୘(𝐗୘𝐗 + (𝐗୘𝐗)୘) + 2𝜆𝐏୘ = 0,                  (2.7) 
ୢ୐(𝐏)
ୢఒ
ቀ𝐏୘𝐗୘𝐗𝐏 − 𝜆(𝐏୘𝐏 − 1)ቁ = (𝐏୘𝐏 − 1) = 0.                   (2.8) 
Knowing that cov(X) is symmetric and taking into account Equation (2.7) and Equation (2.8) 
it is possible to write: 
𝐏୘(𝐗୘𝐗 + (𝐗୘𝐗)୘) + 2𝜆𝐏୘ = 𝐗୘𝐗𝐏 − 𝜆𝐏 = 0,                (2.9) 
which is similar to the eigenvalue problem of Equation (2.2).   
With the results of Equation (2.6) in mind it is possible to write Equation (2.4) as 
𝐏୘𝐗୘𝐗𝐏 = 𝐏୘𝜆𝐏 = 𝜆𝐏୘𝐏 = 𝜆.               (2.10) 
Considering the maximisation problem of equation (2.5), λ is the greatest eigenvalue for the 
eigenvalue problem of equation (2.2) (Trefethen and Bau, 1997). 
It can be observed that the terms 𝐭ଵ𝐩ଵ୘, 𝐭ଶ𝐩ଶ୘ … 𝐭ே𝐩ே୘  of Equation (2.4) can be interpreted as the 
first, second and up to the N-th eigenvector ordered by the magnitude of the associated 
eigenvalue. According to the rule of thumb that an eigenvalue explains a number of variables 
roughly equal to it’s value it is possible to say they are consequently also ordered by the amount 
of variance explained. 
Following this reasoning Equation (2.3) can be written as a sum of A, accepted principal 
components and (n-A) discarded principal components without losing representativeness. 
These n-A principal components can be stored in the matrix E, which will now store the 
unexplained variability in addition to residuals  
𝐗 = ∑ 𝐭௡𝐩௡୘஺ଵ + ∑ 𝐭௡𝐩௡୘ே஺ାଵ + 𝐄 = ∑ 𝐭௡𝐩௡୘஺ଵ + 𝐄෠.               (2.11) 
Methods are avaible to assess the performance of the PCA model. These methods can be 
divided in observation, variable and model diagnostics. (Eriksson et al., 2001) 
Observation diagnostics are used to recognise outliers. Outliers are observations which appear 
to be inconsistent with the rest of the data, relative to an assumed model (Everitt and Skrondal, 
  
Mathematical background 17 
 
2010), hence the importance of their removal when data analysis is carried out. A diagnostic 
used to identify these inconsistent observations is Hotelling’s T2 statistic (MacGregor and 
Kourti, 1995), a mulivariate generalisation of student’s t-test that checks the adherence to 
multivariate normality. 
An observation T௜ଶ statistic is given by : 
𝑇௜ଶ = ∑
௧೔ೌ
௦೟ೌ𝟐
஺
௔ୀ𝟏 ,               (2.12) 
where 𝑠௧௔ଶ is the score variance with respect to principal component a and A is the number of 
principal components used for the PCA. 
A sample is deemed to be an outlier if T௡ଶ is greater than a critical value T௖௥௜௧ଶ  expressed by 
(Wikström, et al., 1998) 
𝑇௖௥௜௧ଶ =
஺(ூିଵ)
ூ(ூି஺)
F(𝐴, 𝐼 − 𝐴, 𝛼)               (2.13) 
where A is the number of selected Principal Components, I is the number of observations in 
the model training set and F(A, I-A, α) is the function that computes the value that should 
exceed α% of the samples from an F distribution with A degrees of freedom in the numerator 
and (i-A) degrees of freedom in the denominator. The threshold value α is selected based on 
the confidence that is needed for the critical value, usually 5% is used giving a confidence of 
95%. 
Variables diagnostics can be used, for example, to assess the explained variation of a variable 
with respect to the selected principal components. This indicator ranges from zero (no 
explanation) to one (complete explanation).  
One of the ways to compute this indicator is by analysing the 𝐄෠ matrix column-wise sum of 
squared elements: 
𝐄෠௔௝ = ∑ 𝐞௜௝௔𝟐ூ௜ୀଵ = ∑ (𝐗௜௝ − 𝐭௜௔𝐩௝௔)𝟐ூ௜ୀଵ                (2.14) 
where j stands for one of the J variables of the X dataset, a stands for the a-th principal 
component up to the selected A of equation (2.11) and I is the total number of repeated 
measurements in the X dataset. 
The matrix from Equation (2.14) can be related to the sum of squares of the original variable 
to obtain a normalised portion of unexplained variance for that variable (Varmuza and 
Filzmoser, 2009). Subtracting that from one gives 𝑅௔ ௝ଶ, which is the above-mentioned indicator 
of variation for a principal components, 
𝑅௔ ௝ଶ = 1 −
∑ ୣ೔ೕೌ
మ಺
೔సభ
∑ 𝐗೔ೕ಺೔సభ
 .               (2.15) 
Given a fixed number of principal components, it is desirable to have the maximum possible. 
This is not always the case as it can happen that a variable may have a very low explained 
variance while all the others variables may have satisfactory values. If that happens it could be 
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appropriate to add another principal component to the analysis, if in accordance to the model 
diagnostic. 
Model diagnostics can be used for a statistical based estimation of the optimum number of 
principal components. In this analysis is essential to evaluate the “goodness of fit” (𝑅ଶ) statistic 
along with the “goodness of prediction” (𝑄ଶ) statistic. To be done in a statistically meaningful 
way data have to be resampled, for example by bootstrapping or by cross validation (Varmuza 
and Filzmoser, 2009). 
Cross validation is one of the most used techniques and consists in splitting the original data 
into group into subgroups and then proceeding with a leave-one-out criterion. 
The subgroup left out will be the validation group to the training one, comprised of all the other 
groups. 
PCA is carried out on the training group, loadings and scores are calculated and residuals are 
computed. From this, a goodness of fit statistic can be extracted calculating an indicator similar 
to that of Equation (2.15) but considering all J variables instead of just one at a time. As for 
the variable diagnostic, values of this goodness of fit statistic range from zero to one and are 
ever increasing as new principal components are added to the analysis. 
It is now clear that, as mentioned above, a goodness of prediction statistic is also necessary; 
this statistic is computed using the validation dataset.  
The validation group scores are calculated according to (2.3) using the training group loadings: 
𝐗௩௔௟𝐏௧௥௔௜௡ = 𝐓௩௔௟ ,               (2.16) 
where the subscripts “val” and “train” refer to the validation and training group respectively. 
As for the training set residuals are computed as 
𝐄෠௩௔௟ = 𝐗௩௔௟− 𝐓௩௔௟𝐏௧௥௔௜௡              (2.17) 
 in addition, the goodness of prediction statistic is calculated as: 
𝑄௔ଶ = 1 −
|| 𝐄෠ೡೌ೗||ೌ 𝟐
||𝐗||𝟐
              (2.18) 
where the a stands for the number of principal components used for this projection as in 
equation (2.14) and (2.15). 
Criteria for selecting the number of optimal principal components using these statistics are 
manifold. For example, Eriksson et al. (2001) proposed a slightly different criterion for Q2 
using the residual sum of squares of the previous dimension, 
𝑄௔ଶ = 1 −
|| 𝐄෠ೡೌ೗||ೌ మ
|| 𝐄෠||ೌషభ మ
,               (2.19) 
instead of  ||𝐗||ଶ in equation (2.18), stopping when the added prediction power is lower than a 
critical limit. 
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2.2 Partial Least Squares Regression (PLS) 
Partial Least Squares Regression (PLS) is a multivariate regression technique that introduces a 
reduced set of variables, called latent variables, by maximising the covariance between a input 
and output dataset. PLS can be used for dimensional reduction, regression analysis or 
classification problems among other uses (Rosipal and Krämer, 2006).  
Let 𝐘[𝐼 × 𝐾] be a mean-centered historical dataset composed of the output generated by the 
input in X. The matrix Y is composed of I rows and K columns. Using the PLS decomposition 
it is possible to write X and Y as: 
𝐗 = 𝐓𝐏୘ + 𝐄
𝐘 = 𝐔𝐐୘ + 𝐅              (2.20) 
Where T and U are [𝐼 × 𝐴] matrices of the A extracted score vectors. The matrices P [𝐽 × 𝐴]and 
Q [𝐾 × 𝐴] are composed of the loadings and E [𝐼 × 𝐽]and F [𝐼 × 𝐾] are the residuals. 
The covariance between X and Y is: 
cov(𝐗, 𝐘) =  𝐗
౐𝐘
ூିଵ
.              (2.21)  
The decomposition of Equation (2.20) is obtained through two weight vectors, w and c, one 
for X and one for Y. Weights w and c are [𝐼 × 1] vectors and every latent variable will have 
different weight vectors adding up to [𝐼 × 𝐴] matrices W* and C* after the A latent variables 
have been selected. 
These weights are subject to the following optimisation problem,  
 max (𝐰୘𝐗୘𝐘𝐘୘𝐗𝐰)  
s. t.   𝐰୘𝐰 = 1            
              (2.22) 
and 
 max (𝐜୘𝐘୘𝐗𝐗୘𝐘𝐜)  
s. t.   𝐜୘𝐜 = 1.            
               (2.23) 
Equations (2.22) and (2.23) are similar to the optimisation problem of Equation (2.5), and the 
methods of Equations (2.6)-(2.10) can be applied. As derived in Equation (2.10) w and c are 
the eigenvectors of the greatest eigenvalue for the matrices above. 
Once computed the weight vectors can be used to obtain the score vectors t and u as the linear 
coefficient of: 
𝐭𝒂 = 𝐗𝐰𝒂,               (2.24) 
𝐮𝒂 = 𝐘𝐜𝒂,               (2.25) 
where a stands for the a-th component of the PLS and, as such, as the a-th step of the algorithm. 
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To obtain the full latent structure it is necessary to proceed iteratively on the deflated data 
matrix. The process of Deflation means subtracting the projection of X and Y to the X and Y 
matrix to be used in the next iteration.  
The deflation step is one of the critical features of the PLS methodology since it allows to 
remove the projection of the data matrix in the direction of the selected component, and to 
maximise the information gained from the method.  
Consider this inequality, proved among others, by Rao (Rao, 1979): 
𝑠௜ଶ(𝐀 − 𝐁) ≥ 𝑠௜ା௞ଶ (𝐀) = 𝑎௜ା௞ଶ .                 (2.26) 
Where 𝑠௜ଶ(𝐀) is the i-th singular value of matrix A and B is a matrix of rank k. 
When this is applied to the PLS it becomes (Hoskuldsson, 1988): 
𝑠ଵଶ൫𝐗୧ାଵ୘ 𝐘൯ = 𝑠ଶ൫𝐗௜୘𝐘 − 𝐩௜𝐭௜୘𝐘൯ ≥ 𝑠ଶଶ൫𝐗௜୘𝐘൯              (2.27) 
This means that the largest singular value at step i+1, after deflation, is greater than the second 
largest singular value at step i.  Equation (2.27) proves the previous assumption of that deflation 
maximises the information gained. 
As mentioned above deflation is carried out by: 
𝐗௔ = 𝐗௔ିଵ −
𝐭ೌష𝟏𝐭ೌషభ౐
𝐭ೌషభ𝐓 𝐭ೌషభ
𝐗௔ିଵ,               (2.28) 
𝐘௔ = 𝐘௔ିଵ −
𝐮ೌషభ𝐮ೌషభ౐
𝐮ೌషభ౐ 𝐮ೌషభ
𝐘௔ିଵ,              (2.29) 
Where a is the a-th step while step 0 is the original dataset for X and Y and vector of zeros of 
the appropriate dimension for t and c. 
Loadings for the reconstruction of the matrices are calculated as: 
𝐩௔ =
𝐭ೌ౐𝑿ೌ
𝐭ೌ౐𝐭ೌ
,              (2.30) 
and 
𝐪௔ =
𝐮ೌ౐𝐘ೌ
𝐮ೌ౐𝐮ೌ
.               (2.31) 
Both scores and loading of each step are concatenated as columns to create the P, Q, T and U 
matrices of Equations (2.20).  
As with PCA, there are some diagnostics useful for troubleshooting the model and the analysis. 
The actual diagnostics are in many way similar to those of the PCA, with only minor variations 
necessary to adress the dimensionality issues between the two methods. 
Hotelling’s T2 for PLS methods is equivalent to the one applied to PCA, since it tests the 
adherence to multivariate normality. Other diagnostics used to troubleshoot Observations are 
the scores plot, which in PLS develop a further level of complication since cross variable scores 
have to be inspected too.  
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Variable diagnostics are easily adapted from PCA. The analysis of column-wise sum of 
residual (2.14) and R2 statistics (2.15) can be also computed for PLS. Since PLS has one more 
residuals matrix, F, these statistics should be computed for this matrix too evaluating the degree 
of explaination that the method gives to the K output variables. 
In the context of PLS model diagnostics can, and should, be used. Following the trend set by 
the other diagnostics type only minimal modifications have to be applied to use the PCA model 
diagnostic. While cross validation stands, it is necessary to use a validation dataset to 
investigate the goodness of the model for both matrices. The modification needed for the 
goodness of prediction statistic is that Equation (2.18) and (2.19) need to be applied to both 
matrices, Y and X. In the case of PLS regression instead, the goodness of fit statistics of 
Equation (2.18) and (2.19) have to be applied to the results of the regression of matrix X on Y 
and thus on the prediction of the output matrix Y instead of the imput matrix X. 
2.3 Bayesian statistical methods 
Bayes rule is a theorem in statistical science that originates from the work of Pierre-Simon 
Laplace on a posthumous work by Thomas Bayes (Bayes, 1763). 
This theorem is formulated as: 
P(𝐲|𝛉) = ୔(𝛉|𝐲)୔(𝛉)
୔(𝐲)
.               (2.32) 
It states that the probability of an observation y given the that the parameters are θ is equal to 
the probability of the parameter vector being θ having observed y, multiplied by the probability 
of the parameters being θ, divided by the marginal distribution of y. The marginal distribution, 
also called the prior predictive distribution, can also be written as: 
P(𝐲) = ∫ P(𝐲|𝛉)P(𝛉)d𝛉,               (2.33) 
for continuos quantities, or 
P(𝐲) = ∑ P(𝐲|𝛉)P(𝛉)௵ఏ                (2.34) 
where the summation sign stands for every possible value of θ, for discrete values.  
Bayes theorem is a propriety of conditional probability, but it also represents a tool for updating 
and revising the probability of an occurrence based on new evidence (Everitt and Skrondal, 
2010). This new evidence is fed in Equation (1.30) by the prior distribution of the parameters 
θ and different degree of knowledge of the priors give rise to different distribution for P(y| θ). 
The idea at the core of Bayesian statistics is that the uncertainty of the investigator about an 
inferred quantity is expressed by using a probability distribution (Jaynes, 2003), and the region 
under the x percent of the probability function is called a x credibility interval (Gelman, et al., 
2013). 
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One of the most used tools of statistics is linear regression and the simplest and most widely 
used linear regression tecnique is the normal linear model (Gelman, et al., 2013). 
The normal linear model represent Y as normally distributed with mean composed as a linear 
combination of the values of X, with B as the combination coefficients: 
E(𝐲𝒊|𝐗, 𝐁) =
𝐁ଵଵ
⋮
𝐁ଵே
𝐱ଵ +
𝐁ଶଵ
⋮
𝐁ଶே
𝐱ଶ +
𝐁ଷଵ
⋮
𝐁ଷே
𝐱ଷ + ⋯ +
𝐁௃ଵ
⋮
𝐁௃ே
𝐱௃.              (2.35) 
Equation (2.33) represents a multivariate case in which N is different from one and as such the 
distribution of Y is multivariate normal instead of normal.  
This can be written as: 
𝒀 = 𝑿𝑩 + 𝑬              (2.36) 
where E is the matrix of the residuals. 
From a Bayesian perspective, this model should also include a distribution for X given a 
parameter vector ξ, since X is also part of the dataset. 
It follows that the regression model should incorporate a joint probability: 
P(𝐗, 𝐘|𝛉, 𝛏)P(𝛉, 𝛏).               (2.37)  
A defining characteristic of regression from a Bayesian point of view is the consideration of 
prior independence of the parameter vector θ that determines P(𝐘|𝐗, 𝛉) and the parameter 
vector ξ that determines P(𝛏|𝐗). From this condition follows the posterior distribution: 
P(𝛉, 𝛏|𝐗, 𝐘) = P(𝛏|𝐗)P(𝛉|𝐗, 𝐘).               (2.38)  
It is possible to study only the second part of the equation, given that usually data comprising 
X are observed and directly chosen and as such their probability P(𝐗) is known and there is no 
parameter vector ξ. 
Applying Bayes Rule to equation (2.36) we have: 
P(𝛉|𝐗, 𝐘) ∝ P(𝐘|𝛉, 𝐗)P(𝛉).               (2.39)   
Let θ be [B, σ2] with σ2 equal to the variance of unit weight of Y and its distribution as normal. 
This identifies a subset of the normal linear model called the ordinary linear model, 
characterised by homoscedasticity and equal variance throughout Y. 
In short, for this model we can write: 
(𝐘|𝐁, 𝛔𝟐, 𝐗)~N(𝐁𝐗, 𝛔𝟐𝐈୒).              (2.40) 
At this point, if X is full rank, the analysis of this distribution still yields the same maximum 
likelihood estimate as the classical frequentist approach, taken by maximising the logarithm of 
the exponential form of the normal distribution. This maximum likelihood estimate are: 
𝐁෡ெ௅ா = (𝐗୘𝐗)ିଵ𝐗୘𝐘 ,               (2.41) 
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and 
𝛔ෝெ௅ாଶ =
𝟏
ே
𝐞୘𝐞 .              (2.42) 
WhereN is the number of observations and e is the model error with the B parameters from 
equation (2.40) (Lynch, 2007). 
In the full Bayesian approach at this point a definition of a prior for equation (2.37) is necessary. 
A standard uninformative prior for regression is the uniform prior, which assigns an equal 
probability to every possible value of the beta parameters. This is not always the case. 
From these information it is possible to compute a posterior predictive distribution. The goal 
of Bayesian regression is not simply the estimate of the values of the parameters and their 
deviation, but to infer on unknown quantities, thus the target distribution is the distribution of 
the response variable y given a new data point taken from the same data pool as X but not 
included in the derivation of the parameters, 
P(𝐲|𝐱, 𝐁, 𝛔𝟐).               (2.43) 
This probability is obtainable through calculations only in limited cases due to the difficulty of 
the required integrations and it has to be computed through a simulation. The most used 
simulation is the Markov Chain Monte Carlo method. The Markov Chain Monte Carlo 
(MCMC) is a method for constructing and sampling from an arbitrary posterior distribution θ 
adjusting the draws to better represent the posterior distribution P(𝛉|𝐘) (Gelman, et al., 2013). 
The MCMC method is based on the concept of Monte Carlo process, a process composed of 
random draws and that of Markov chains. A Markov chain is a stocastic process for which the 
distribution of the parameters 𝛉୲ at iteration t, given the distribution of all the other parameters 
θ, depends only on the value at 𝛉୲ିଵ.  
Applied to the MCMC method this means that the transition distribution Tt,  
T௧(𝛉௧|𝛉଴, 𝛉ଵ, ⋯ , 𝛉௧ିଵ) = T௧(𝛉௧|𝛉௧ିଵ),               (2.44) 
that is the distribution that governs the direction of the Markov chain evolution, must have a 
specific stationary distribution, which is the distribution the chain tends to with infinite draws. 
For any specific distribution P(𝛉|𝐘) or un-normalized density Q(𝛉|𝐘),  it possible to build 
some Markov chains with the desired stationary distribution. Within the context of successive 
refinement of the approximation, the sampling algorithm has a crucial spot. For these reasons 
the research on the topic of optimal sampling algorithm is still open.  
One of the most used algorithm is the Gibbs Samples, also called alternating conditional 
sampling. In this algorithm the parameter vector θ is divided into d sub-vectors such as: 
𝛉௚௜௕௕௦ = (𝛉ଵ, ⋯ , 𝛉ௗ).                (2.45) 
At each step t then the Gibbs sampler cycles through the d parameters sub-vectors and the new 
sub-vector values are sampled as conditional on all the others sub-vectors. Each iteration t has 
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then d steps, at every step a different ordering of the d sub-vectors is selected and the new value 
of the proposed posterior probability is computed. 
The new values are conditional on the current values of the others: 
P(𝛉௝௧|𝛉ଵ௧ , … , 𝛉௝ିଵ௧ , 𝛉௝ାଵ௧ିଵ, … , 𝛉ௗ௧ିଵ, 𝐘),              (2.46)  
thus the sub-vector j at iteration t is calculated as conditional to the value at time t of the 
previous sub-vectors and to the value of the following ones at time t −1. This algorithm is the 
simplest of the MCMC sampling and is thus mainly used when it is possible to direclty sample 
the conditional posterior distribution, such as in conditionally conjugate model. 
Other examples of sampling algorithms are the Metropolis and its generaliation the Metropolis-
Hastings. The Metropolis algorithm is a modified random walk model with an acceptance 
criterion to speed up convergence to the desired stationary distribution. The random walk is a 
stochastic process in which a particle r starts at a position 𝑟 = 𝑟଴ and, at each step t, has the 
possibility p of moving up and (1−p) of moving down; p is called the jumping distribution. 
The Metropolis algorithm starts with a draw for which P(θ0|Y) is greater than zero, taken form 
a given starting distribution. Then for t steps a proposal 𝛉∗is generated from a symmetric 
jumping distribution: 
𝐉௧(𝛉∗|𝛉௧ିଵ) = 𝐉௧(𝛉௔|𝛉௕) = 𝐉௧(𝛉௕|𝛉௔),              (2.47)  
for every a, b and t. 
The algorithm then calculates the ratio of densities, 
ratio = 𝐏(𝛉
∗|𝐘)
𝐏(𝛉𝒕ష𝟏|𝐘)
               (2.48) 
and subsequently generates an uniform random number to simulate the random walk, using it 
as acceptance criterion for the proposed θ* 
𝛉௧ = ൜𝛉
∗     with probability min(ratio,1)     
𝛉௧ିଵ   otherwise                                      
              (2.49) 
The Metropolis Hastings algorithm has some fundamental differences, first the jumping 
distribution of Equation (2.47) does not need to be symmetric, and as such the second and third 
therm are not present, second the ratio of Equation (2.48) is calculated as a ratio of ratios: 
ratioெு =
ౌ(𝛉∗|𝐘)
𝐉೟(𝛉∗|𝛉೟షభ)
ౌ(𝛉೟షభ|𝐘)
𝐉೟(𝛉೟షభ|𝛉∗)
              (2.50) 
As this is always defined even for asymmetric jump distributions. 
It is possible to prove that the Gibbs sampler is a special case of the Metropolis algorithm with 
a particular jumping distribution and ratio equal to 1. 
The Metropolis and Metropolis Hastings algorithm are more flexible than the Gibbs sampler 
and can be used even in cases where the conditional posterior distribution is not in the same 
distribution family as the prior distribution. 
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Many other sampling algorithm have been proposed, each used in different cases and with their 
own pros and cons, for example Slice Sampling (Gilks and Wild, 1992), Reversible Jump 
Metropolis (Green, 1995) or preconditioned Crank-Nicolson algorithm (Cotter, et al., 2013). 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
  
Chapter 3 
Design space determination: a 
Bayesian approach 
 
In this chapter, a brief introduction to the link between mathematical modelling and the Quality 
by design paradigm discussed in the previous chapter is given. Moreover, a recently developed 
technique that can be used to identify the design space of a new pharmaceutical product in a 
Bayesian framework is briefly reviewed.  
3.1 Quality by Design and modelling 
The new paradigm of Quality by Design for pharmaceutical products and process design can 
be seen, from the chemical engineering point of view, as the application of Process System 
Engineering (PSE) to manufacture and development of pharmaceutical products (García-
Muñoz and Oksanen, 2010). In line with the approach suggested by the regulatory agencies, it 
is crucial to analyse CPPs and raw materials properties and to link them, through a scientific 
analysis, to the CQAs of the products. Models can be derived either from first principles - if 
the process knowledge is mature enough - through data driven methods or by a combination of 
the two. Since their origin is found in the application of PAT frameworks (see chapter §1), 
models are part of the framework too, and as such are PAT tools themselves. 
The use of models is crucial in the effort to shift the product design paradigm from an 
experience-based one towards a science-based one, integrating it in the design of the production 
process. This fact is fully understood by the regulatory agencies, which encouraged model-
based support for QbD implementation. The International Conference on Harmonisation in its 
2011 guide for ICH Q8/Q9/Q10 implementation divided models into different categories, 
based on their contribution to assuring the quality of the end product. 
Regarding the assurance of quality, a model can be divided into low, medium or high impact. 
Low-impact models are typically those used to support product and/or process development 
(e.g., formulation optimization). Medium-impact models are useful in assuring the quality of 
the product but are not the sole indicators of product quality (e.g., most design-space models, 
many in-process controls). High-impact models instead are those whose prediction is a 
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significant indicator of the quality of the product (e.g., a chemometric model for product assay) 
(ICH, 2011). 
Process System Engineering provides many tools for model development and application, 
which have already been developed and have undergone decades of improvements and 
evolution in other areas of industrial manufacturing. Provided that some challenges, unique to 
the field, have been studied and incorporated in the PSE, pharmaceutical sector stand to gain 
remarkably from PSE adoption.   
3.2 Design Space identification 
Modelling the multivariate relations between the raw materials properties, the CPPs and the 
CQAs of the products could seem straightforward, but some issues arise. Scientists were at first 
tempted to employ some well-known metrics to calculate the design space, for example using 
a combination of proven acceptable range (PAR). PAR are defined as “a characterised range 
of a process parameter for which operation within this range, while keeping other parameters 
constant, will result in producing a material meeting relevant quality criteria”. As the definition 
suggests PAR is a univariate approach in its core and as such is too simplistic in treating the 
multivariate nature of an industrial process.  In fact, during a subsequent review of the Q8 
document, ICH clarified that a combination of proven acceptable ranges does not constitute a 
design space (ICH, 2009). Scientists then changed the approach to one well known and easily 
implemented; the overlapping mean responses (OMR) approach. The OMR approach is a 
classical response surface methodology, which primarily focuses on inference about mean 
response surfaces. This method also had the benefit of having many point-and-click oriented 
statistical packages such as such as Design Expert™ or JMP equipped with integrated 
functionalities that made the construction of an OMR plot relatively easy; furthermore, at the 
time some studies proposed the OMR as the correct approach (Peterson and Lief, 2010).  
The OMR method consists of merely overlapping two or more mean responses chart and to 
look for “sweet spots” (Anderson and Whitcomb, 1998) where the desired responses are 
obtained and propose that area as the design space. The OMR can be expressed mathematically 
as (Peterson et al., 2017): 
{𝐱 ∊ 𝛘: E(𝐲|𝐱) ∊ 𝐒}                  (3.1) 
where x is an arbitrary configuration of the process inside the “sweet spot”, 𝝌 is the “sweet 
spot”, that is the combination of desired responses, expressed by the expectation E of the 
responses y given the data vector x, that are inside the desired response interval S. 
Another approach that enhances OMR is to use desirability functions. Desirability functions 
are functions that map the mean response of a single CQA to a scalar value ranging from zero 
to one, with zero an undesirable outcome and one a wholly desirable,  ideal, outcome. 
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𝒀௜(𝐱) = 𝑑௜(𝐘௜);
𝑑௜ ∈ [0,1].         
                (3.2) 
 Desirability functions have different forms whether the objective is to maximise, minimise or 
obtain target desirability. The most used forms are those proposed by Derringer and Suich 
(Derringer and Suich, 1980). Let Ui, Li and Ti be the upper, lower and target desired value for 
the i-th CQA, di(Yi) is then equal to: 
𝑑௜(𝐘௜) = ൞
0 if 𝐘௜(𝐱) > U௜;                     
𝐘೔(𝐱)ି୙೔
୘೔ି୙೔
 if T௜ ≤ 𝐘௜(𝐱) ≤ U௜;
1 if Y௜(𝐱) < T௜ ,                     
                    (3.3) 
if the target is to minimize the value of Yi(x), 
𝑑௜(𝐘௜) = ൞
0 if 𝐘௜(𝐱) < L௜;                     
𝐘೔(𝐱)ି୐೔
୘೔ି୐೔
 if T௜ ≥ 𝐘௜(𝐱) ≥ L௜;
1 if Y௜(𝐱) > T௜,                     
                   (3.4) 
If the target is to maximize the value of Yi(x) and 
𝑑௜(𝐘௜) =
⎩
⎪
⎨
⎪
⎧
0 if 𝐘௜(𝐱) > U௜;                     
𝐘೔(𝐱)ି୐೔
୘೔ି୐೔
 if T௜ ≥ 𝐘௜(𝐱) ≥ L௜;
𝐘೔(𝐱)ି୙೔
୘೔ି୙೔
 if T௜ ≤ 𝐘௜(𝐱) ≤ U௜;
0 if Y௜(𝐱) < L௜,                      
                 (3.5) 
If the response is of “target is best” kind. These responses are then combined, usually as a 
geometric mean, to obtain the total desirability of the CPP and material attributes configuration. 
D = ඥ𝑑ଵ(𝐘ଵ) × 𝑑ଶ(𝐘ଶ) × ⋯ × 𝑑௡(𝐘௡)
೙                 (3.6) 
where n is the total number of CQAs. The total desirability D is then maximised (Derringer 
and Suich, 1980).  
The endorsement from the ICH and the ISPE PQLI came even though both the OMR and the 
desirability function approaches present two debilitating flaws. They both fail to account for 
the model parameters uncertainty and to describe the influence of the correlation structure of 
the regression models residuals. Furthermore, for the establishment of a DS, it is necessary to 
give an assurance of quality as stated by the regulatory agencies. The flaws mentioned above 
render the assurance of quality almost impossible, as shown by Peterson (Peterson J. J., 2008). 
In fact, even the best point in the “sweet spot” can have small reliability with regards to meeting 
QTPP. The following two examples that prove that in a simple way are taken from the works 
of Peterson J. J. (2008) and Peterson and Lief (2010). 
Consider an acceptance region S of Equation (3.1) composed of (−∞, 1] × (−∞, 1] ×
(−∞, 1] × (−∞, 1] and a length four response vector 𝐲~𝑁(0, 𝚺). Now consider the variance 
covariance matrix Σ, if it is composed of all ones in the diagonal and all 0.9 in the off diagonal 
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the probability P(𝐲𝐒) = 0.75, if the off-diagonal values are smaller, it is found that P(𝐲𝐒) 
can be substantially lower. 
Furthermore, consider a mean response vector y composed of n mean response values of the 
CQAs to the CPP and material attributes configuration. Suppose to need the CQAs to be lower 
than a specific threshold ui. OMR and desirability functions work with mean responses without 
considering that these responses are instead random variables, y~N (μ,Σ). Setting a response yi 
to be below the desired threshold ui means, since yi is normally distributed, that the 
P൫yi<ui൯≥0.5 in virtue of the shape of a normal distribution. Extending this to the whole vector 
composed of n mean responses means that P൫y1,y2,…,yn<ui൯≥0.5
n using some basic 
probability propriety. This is true only if the responses have no correlation, i.e. they are 
independent. If they are positively correlated, this will result in a more significant probability, 
while the contrary is true if they are negatively correlated. From these examples, it is clear that 
a new approach is necessary, one that accounts for the correlation structure of the data, the 
uncertainty of model parameters and the variability of the process distribution.  
Furthermore, it is necessary to provide the assurance of quality that the regulatory agencies 
require.  
3.3 Assurance of Quality in the Bayesian Approach 
Two options are identified for the manufacturers to give the required assurance of quality. First, 
they should demonstrate that the operating conditions are fully under control, without statistical 
modelling of his process. Second, evidence should be shown that the quality of the outcome or 
the product remains within acceptable limits, for changes in input variables within identified 
limits. The first option is generally difficult or too expensive to achieve. The second option is 
more realistic because it considers the inevitable variability in the achievement of quality 
(Peterson and Lief, 2010). Peterson (2008) first introduced the concept of Bayesian 
probabilistic design space as the most suitable technique to quantify the “assurance” of quality 
as defined by the regulatory agencies. The Bayesian approach offers other theoretical benefits, 
such as the robustness of the derived model, which can easily accommodate for “noisy 
variables” and the ability to account for missing values. Furthermore, the Bayesian approach 
does not present the flaws found in the OMR approach; it processes inherently correlations, 
uncertainty and variability.  The next section describes the mathematical formulation of this 
approach.  
3.3.1 Bayesian design space: mathematical formulation 
According to Peterson (2008) the Bayesian DS can be defined as: 
DS = {𝐱 ∶ P(𝐲|𝐱, data) ≥ 𝜃௧௛},                  (3.7) 
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with x one of the possible configuration of the CPP and material attributes for the process, y a 
vector of CQAs and θth a user-defined probability threshold. A necessary comment must be 
made on the value of θth. The regulatory agencies have not stated a minimal threshold for a 
presented DS.  However, as proved by Peterson (2008), a minimum value can be set to 80%.  
To use Equation (3.7) it is necessary to have a model that links the process inputs, CPP and 
raw materials properties, to the CQAs of the products. Throughout this study, the model used 
is a multivariate linear regression as in Equation (2.36): 
𝐘 = 𝐗𝐁 + 𝐄௦,                (3.8) 
with the same variables and dimensions and the residuals supposed independent and following 
a normal distribution. In order to establish a DS, it is necessary to apply the Bayesian method 
discussed in chapter §two to obtain a posterior predictive distribution as the one of Equation 
(2.43) with the multivariate parameter Σ in place of the variance of unit weight.    
The posterior predictive distribution conditional on data and regression parameters is 
𝑔(𝐲|𝐱, data) = ∬ 𝑓(𝐱|𝐲, 𝐁, 𝚺𝑩)P(𝐁, 𝚺𝑩|data)𝑑𝐁𝑑𝚺𝑩,                  (3.9) 
where P(B,ΣB|data) is the joint posterior distribution of the model parameters. From Equation 
(3.5) Equation (3.4) can be obtained with integration at the desired threshold. 
P(𝐲|𝐱, 𝐗, 𝐘) = ∫ 𝑔(𝐲|𝐱, 𝐗, 𝐘)𝑑𝐲ఏ೟೓                (3.10) 
It is easy to see, from Equations (3.7) and (3.9) that it is necessary to obtain the joint posterior 
distribution of the model parameters to solve Equation (3.10).  
The joint posterior distribution can be computed using the Bayes’ theorem of Equation (2.32), 
thus giving: 
P(𝐁, 𝚺𝑩|data) ∝ ℒ(𝐁, 𝚺𝑩|𝐘)P(𝐁|𝚺𝑩),               (3.11) 
where ℒ(𝐁, 𝚺𝑩|𝐘) is the likelihood function of the parameters conditional to the response 
contained in the data and P(B|ΣB) is the joint distribution of the model parameters. The 
likelihood function of Equation (3.11) can be expressed as (Lenk, 2001): 
ℒ(𝐁, 𝚺𝑩|𝐘) = |𝚺𝑩|
ି೙మ  e(
భ
మ ୲୰ୟୡୣ [𝚺𝑩
ష𝟏(𝐘ି𝐗𝐁)౐(𝐘ି𝐗𝐁)].               (3.12)  
The model error term, which accounts for the model variability and the error stemming from 
the parameters variability, Es in Equation (3.8), has to be calculated in order to correctly 
estimate Y. The model error is assumed as normally distributed with error ΣS: 
𝐄ௌ~ N(𝟎, 𝚺ௌ).               (3.13) 
To account for an unknown variance parameter it is known (e.g. Gelman et al.,( 2013)) that the 
appropriate non-informative prior distribution is the Inverse-Wishart distribution, the 
multivariate generalisation of the Inverse-Gamma distribution. The likelihood of the model 
error is then calculated as: 
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ℒ(𝚺௦|υ, 𝐆, data) =
𝚺ೞ
ഔష೙షభ
మ
𝐆
ഔ
మ
eቂି
భ
మ୲୰ୟୡୣ(𝐆
షభ𝚺ೞቃ,               (3.14) 
where υ > n-1 is the degree of freedom of the distribution, n is the dimension of Σs and G is a 
positive definite, symmetric, n × n scale matrix. Once all the factors have been calculated, 
Equation (3.10) can be solved and a Bayesian DS can be established. 
This Bayesian approach to design space has several advantages already mentioned above, but 
can still be improved.  
There are problems in the representation of the obtained results; this derivation of the DS 
suffers from the “curse of dimensionality” as did the OMR approach. Furthermore, the 
contribution of measurement error to the established DS has to be considered from a Bayesian 
point of view. 
3.3 Design space determination: a joint Bayesian/latent variable 
approach 
In order to address the dimensionality issue of the Bayesian DS, the main strategies used are 
results table or arrays of bivariate matrices, keeping the interpretation of the results not 
straightforward and hard for non-scientist or technicians. In a recent paper from Bano et al. 
(2018) a new approach has been proposed, utilising the dimensionality reductions of the PLS 
method explained in chapter §2.2 in conjunction with the Bayesian methodology to establish a 
DS explained above. This methodology has the clear benefit of permitting the easy 
representation of the resulting Bayesian DS, permitting ease of interpretation from technicians 
and non-technicians alike. This data-driven method employs historical data from known 
processes defined similar (e.g. by the method proposed by Jaeckle and MacGregor(1998)) 
Keeping in mind the definition of knowledge space (KS) and historical dataset in chapter §two 
it is possible to rewrite Equation (3.7) as (Bano et al, 2018): 
{𝐱 ∈ KS ∶ P(𝐲 ∈ AR|𝐱, 𝐗, 𝐘) ≥ θ௧௛}.               (3.15) 
where the Acceptance Region (AR) is the region in which all product quality attributes meet 
their acceptance criteria. The KS is identified in the latent variables space starting from the 
historical dataset, it is then discretized and the belonging to the AR of each discrete point is 
assessed according to Equation (3.15). Discretization points belonging to the DS are marked in 
green, those rejected in red.  The method is summarized in Fig 3.1.  
The step by step methodology is as follows: 
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1) Given an historical dataset [X, Y], a PLS model is built in order to relate X to Y. 
The number of latent variables A (see chapter §2.2) is chosen in order to maximise the 
information retained while maintaining the ease of representation given by the latent 
variable modelling. Once calibrated a region defined by the 95% confidence limit on 
the Hotelling’s T 2 statistics (Equation 2.13) is identified as the KS. 
2) The KS is then discretised; a very large number Na (e.g. 2000 in the current study) of 
samples are generated in the latent space inside a square of unitary sides. With a small 
number of geometrical transformations, the square is scaled to the confidence hyper-
ellipsoid size. 
Figure 3.3: Flowchart for the proposed methodology for the determination of a DS for a new 
pharmaceutical product taken from Bano et al., 2018 
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3) A representative number of samples Ns <Na is chosen. The number of chosen samples 
is a trade-off between good, uniform coverage of the KS and computational load. In 
this study, a Kennard-Stone algorithm (Kaiser, 1960) has been used for space filling. 
The Kennard Stone algorithm is a sequential sampling algorithm that selects a subset 
of Ns samples, given Na candidates by selecting, at every iteration, the farthest points in 
term of Euclidean distance. Given the importance of the trade-off between coverage 
and computational load, a method has been devised and reported in the original 
publication (Bano et al., 2018) for the selection of the optimal number of points. 
4) For each of the Ns selected samples, the joint posterior predictive distribution (PPD) 
has been computed via Bayesian calculation as explained in section §3.2. The rationale 
used for the calculation was a sequential metropolis, in which new candidates for the 
various parameters were generated with an MCMC procedure with a Metropolis-
Hastings sampling algorithm (Equations 2.46 and 2.49). Figure 3.2 presents the 
sampling sequence.    
5) Given the desired quality target ydes (or quality interval) if the condition expressed in 
Equation 3.3 is satisfied the point is considered inside the DS, if not it is rejected as it 
does not belong to the probabilistic DS. 
An example of a DS established with this methodology is presented in Figure 3.3. 
3.4 Latent Space representation of the DS: a case study 
As mentioned above this method has the benefit of giving an easy way of illustrating the 
proposed DS to non-technicians. In almost all cases the accuracy of the latent space 2-
5) Sequential Metropolis
5.1) A new candidate for B is generated
from a maximum likelihood method and
assessed via a multivariate normal pdf
5.2) A new candidate for Σs is generated
with MATLAB's iwishrnd.m functon
and assessed with Equation (3.14)
5.3) A new candidate for Y is
generated by multivariate normal and
assessed with Equation (3.12) using
the discrete point as X
Figure 3.4. Sampling logic in the Sequential Metropolis algorithm used to compute the PPD 
for the reported method of establishing a Bayesian DS. 
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dimensional representation has been satisfactory, but not in all cases. Hereby a case in which 
the lack of latent space representativeness fails to represent accurately the calculated DS. 
 
3.4.1 Case study: Simulated Roll Compaction 
This case study concerned the dry granulation of a pharmaceutical blend by roller compaction. 
The data used to model this process were generated by Facco et al. (2015), based on the model 
of Johanson (1965).  Roll compaction is a method to provide pre-densification and improve the 
flowability of powders commonly employed in the pharmaceutical and chemical industries. It 
coalesces small size particles in larger agglomerate ready for the subsequent milling and 
tabletting processes (Souihi, 2014).  
Figure 5.3: graphical representation of a DS established with the proposed methodology; 
the green diamonds are points that satisfy Equation 3.3 and thus contained in the DS. The 
red diamonds do not satisfy Equation 3.3 and are therefore rejected.  
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In a roll compaction process an initial powder mix, in the pharmaceutical industry usually a 
compressible filler and some API, passes through the gap between two counter-rotating rolls. 
The powder can be fed, depending on the setup of the machinery, by gravity or by screw 
feeding. The powder is gripped in the decreasing roll gap by the friction on the roll surfaces 
and conveyed to the region close to the minimum roll gap, where compression happens, and a 
compact ribbon is formed. The formed ribbon is then pushed forward and released from the 
roll. It is generally considered that there are three zones of material behaviour in the roll 
compaction process, the slip, nip and release zones as shown in Figure 3.4 
The powder is fed in the slip zone, characterised by particles slipping on the surface of the roll, 
i.e. wall velocity of the particles is different from that of the rolls. Particle rearrangements 
occur, and relatively little pressure is efficiently transferred to the powder in the slip zone. The 
nip zone, short for non-slip, starts at a roll angle α (γ FR from Table 3.1) when the wall velocity 
of the powder becomes equal to that of the rolls. After initial rearrangements, the bulk of the 
pressure is exerted at roll angle θ. Powder densification mainly takes place in this zone. The 
powder is dragged to the smallest gap and compressed by the substantial increase in the 
pressure. The release zone starts when the roll cap begins to increase again in which elastic 
recovery (linked to spring back factor of Table 3.1) can happen. One important factor in roll 
compaction is that binding of particles results only from the compaction forces requiring a 
certain degree of compressibility of the powder blend.  
This technique offers advantages compared to wet granulation since it does not employ liquid 
binders and does not require drying stages, this could positively affect ease of processing in the 
presence of drug substances that are sensitive to moisture, solvent or heat. 
Figure 3.6: Schematic representation of a Roll Compaction process. The powder is fed to 
the process in the slip region, is gripped by friction forces in the nip region and compacted. 
In concordance with the variable names of Table 3.1: Roll gap is sroll, Roll radius is half of 
Droll, the friction angle α is γ FR and the effective friction angle θ is γ EFR. (Souihi, 2014) 
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3.4.2 Case study results 
The historical dataset is composed by ninety input variables (compressibility factor, roller 
diameter, roller width, roller speed, pressure force, friction angle between solid granulate, and 
roller compactor, effective friction angle and springback factor) and one response variable 
(intravoid fraction of the solids out of the compactor). A summary of the input/output variables 
and the characterisation of the input dataset is reported in Table 3.1. 
Table 3.1: Latent Space misrepresentation case study: list of the input and 
response Variables (Data from Facco et al., (2015) based on the model of 
Johanson (1965) and characterisation of the input dataset (Columns 5 and 6)) 
ID Variable name Units Symbol Mean Std. 
Inputs 
1 Compressibility factor [-] k 9.85 2.528 
2 Roller width [m] sroll 0.134 0.015 
3 Roller diameter [m] Droll 0.398 0.0734 
4 Roller speed [rpm] νroll 10.239 6.434 
5 Pressure force [kN] Froll 13867 6951.2 
6 Friction Angle [rad] γ FR 27.507 8.778 
7 Effective friction angle [rad] γ EFR 48.167 31.763 
8 Spring back factor [-] Fsb 0.109 0.0287 
Response 
R1 Intra void fractions of solids [m3/m3] ϕs 0.521 0.117 
 
The problem faced in this early case study was the application of the proposed methodology 
for the mitigation of the Impact of measurement error in Bayesian DS determination on one of 
the case studies from the paper of Bano et al. (2018). That is the development of a granulate 
with intra void fraction of solids of 0.641 [m3/m3] with a probability of reaching specifications 
of at least 90%. As per the followed methodology, a PLS model has been calibrated with the 
whole dataset. Two latent variables were chosen for ease of representation, but these two latent 
variables captured only 47.36% of the variation of X. The methodology has been applied 
nevertheless, selecting a multivariate normal prior distribution for the parameters and an 
Inverse-Wishart prior to the variance-covariance terms. These prior distributions were made as 
uninformative as possible since no prior knowledge was available to justify a different 
approach.  
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The results are presented in Figure 3.4.  The blue circles represent a subset of the real DS of 
the process, derived from first principles modelling by trial and error.  As it can be clearly seen 
the proposed DS does not incorporate most of the real DS points. This confirms one of the 
issues mentioned in the paper by Bano et al. (2018) on the limitations on the use of the proposed 
methodology. The amount of the cumulative X-variability explained has a relevant influence 
on the projection of the knowledge space and lowers the precision of the representation of the 
original input space. It is possible, when the amount of cumulative X-variability explained is 
low, to not represent part of the KS that belong to the DS. The study from Bano et al. (2018) 
suggests as a rule of thumb to set a minimum cumulative X-variability explained to 90%, 
modified the single investigator risk aversion. To achieve this target it could be necessary to 
increase the number of selected latent variables, lowering the ease of representation of the 
proposed DS. 
Figure 3.5: The DS misrepresentation case study: the green diamonds 
represent the proposed design space. While the red ones are rejected points. 
Due to the small cumulative X-variability explained, the proposed DS is 
represented with a great uncertainty. As a counterproof the reported Blue 
circles are a subset of the actual DS, derived by trial and error with a first 
principles model. 
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This misrepresentation gave rise to further study on the topic, and two essential results can be 
reported. First, the definition of a KS in n-dimensions proves difficult since most computational 
methods calculate sums of convex spaces; the risk is to represent the KS as a sum of acceptable 
ranges instead of having a continuous function defining it. Secondly, the number of points 
necessary to discretise the space increase manifold.  
This could be explained in a simple thought experiment. It is possible to think of a filling 
strategy for the KS such as the centre of unitary radius n-dimensional spheres are used as 
discretisation points up to the point in which no more unitary radius n-dimensional spheres can 
be added. Using the concept of kissing number, defined as the number of non-overlapping 
unit spheres that can be arranged such that they each touch another given unit sphere, (Pfender 
and Ziegler, 2004) it is possible to understand that to fill space, discretising it in a meaningful 
way, many more points have to be selected. The higher the dimension, the higher the needed 
points to discretise the space. In the above examples the kissing number of 8-dimensional space 
is 240 compared to the six of a 2-dimensional space (Pfender and Ziegler, 2004), so if the same 
“degree of filling” is desired, many more points have to be selected, possibly manyfold. These 
results suggest that applying a latent space approach to map the original input space and the 
KS has benefits that go beyond the ease of representation and of inversion of the model. 
3.5 Objective of the Dissertation 
As discussed in the previous sections, handling the different types of uncertainties that affect a 
DS identification exercise is a key step for the implementation of the concept of “assurance” 
of quality put forth by the regulatory agencies.  
The aim of this Dissertation is to extend methodologies discussed in the previous sections by 
accounting for an additional source of uncertainty, namely the uncertainty added by the 
presence of measurement errors on the calibration dataset. 
An extention to the bayesian framework described above has been developed and the 
methematical details will be thoroughly discussed in the next chapter. 
 
 
 
 
 
  
 
 
 
 
 
 
  
Chapter 4 
Handling measurement uncertainty in 
Bayesian design space determination  
 
In this chapter a review of the sources and impact of the measurement error will be presented 
in brief. Proceeding with the chapter a methodology for its incorporation in the Bayesian 
approach to the determination of the design space of a new pharmaceutical product will be 
proposed, followed by an explanatory example of its application. 
4.1 Measurement uncertainty: introduction  
In the manufacturing sector measurements have an essential role as they are used as a diagnosis 
of a process, from its start to its end. With the QbD initiative data from measurement retains 
their importance because several decisions of compliance or non-compliance are based on 
measured results and process modelling. Even more than before the industry demands the 
acquisition of reliable in-process analytical data (ICH, 2009). As a consequence of these 
requirements, manufacturers should demonstrate the quality of their results and their fitness for 
purpose by giving a measure of the confidence that can be placed on the results. Furthermore 
based on the needs for an “assurance” of quality it is important to be able to account for all 
sources of uncertainty and their impact on the exercise of establishing a design space. 
4.1.1 Classification of the sources of measurement errors 
Measurement errors can be divided into those arising during the measurement process and 
those that arise due to a later corruption of the measurement signal, e.g. while traveling from 
the sensor to a transducer. From those arising during the measurement process the most relevant 
are systematic and random errors. Systematic errors are errors in the output readings that are 
consistently on one side of the correct observation. System disturbance is one of the most 
frequent sources of systematic measurement error (Morris and Langari, 2016). The act of 
measuring a system perturbs the system in question. This disturbance could be minimal, as the 
one caused by using a cold glass thermometer to measure the temperature of boiling water, or 
as major as the pressure drop introduced in a pipe by a measure of flow with an orifice plate. 
In the first case, the cold glass thermometer would lower the water temperature, even if at a 
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minimal extent, while in the second case an intense pressure drop would be generated in the 
fluid. In view of the above examples, it is clear that the magnitude of the disturbance varies 
between different systems from and has to be accounted when designing the measurement 
system. To design a measurement system that minimizes disturbance a knowledge of the 
mechanism that generates the disturbance and an evaluation of the effective impact on the 
measurement are needed. In the examples above in the first case, the disturbance is so minor 
that the measurement system – the glass thermometer – cannot detect it. In the second case, the 
pressure drop is known and extensively modelled, so its effect can be efficiently balanced. 
Another primary source of systematic error is the presence of environmental inputs. An 
environmental input is defined as an apparently real input to a measurement system that is 
actually caused by a change in the environmental conditions surrounding the measurement 
system (Morris and Langari, 2016). Static and dynamic charateristics of an instrument are only 
valid for particular environmental conditions, these specified conditions must be reproduced 
during calibration in order to avoid wrong results. Away from the specified conditions the 
performance of the instrument can vary and cause an error in the measured quantity. The 
amount of this variation from the true measure is quantified by two constants, zero drift and 
sensitivity drift. In the presence of zero and sensitivity drift it is often difficult to determine 
how much of the response is due to environmental input and how much to an actual change to 
the measured variable. The magnitude of environmental inputs should be measured before the 
real input can be determined. Generally it is very difficult to avoid the influence of 
environmental inputs, because it is rarely pratical, or even possible, to control che 
environmental conditions sorrounding the measurement system (Morris and Langari, 2016) 
and accurate design choices are needed to minimize these influences. Other sources of 
systematic errors can include poorly calibrated or uncalibrated instruments, poorly maintained 
measurement systems of drift in the instrument characteristics. As mentioned above, even with 
good calibration and maintenance standards, coupled with properly trained and attentive 
technicians, some error remains that are inherent in the manufacture of an instrument. These 
errors are quantified by the accuracy value published in the instrument data sheet along with 
zero and sensitivity drifts. 
In addition to systematic errors, random errors also occur in normal measurement practice. 
They are perturbations of the measurement either side of the true value caused by random and 
unpredictable effects, such that positive and negative errors occur in approximately equal 
numbers for a series of measurements made of the same quantity. Such perturbations are mainly 
small, but large perturbations occur from time to time (Morris and Langari, 2016). Random 
errors can be caused by faulty observations of an instrumental reading by an inattentive 
technician (in lab scale experiments), from electrical noises (in plant scale measurements) or 
from random environmental changes. Random errors can be mitigated by repeated 
measurements and by statistical analysis. Because of the unpredictable nature of these random 
 
Handling measurement uncertainty in Bayesian design space determination 43 
 
errors, the best approximations are obtained in probabilistic terms. A measurement could be 
assigned a confidence of 95% and a span of ±1, but in 5% of the cases the actual value would 
be outside the set boundaries. An accuracy of 100% can never be attained in measured 
quantities that are subject to random errors (Morris and Langari, 2016). 
In addition to systematic and measurement errors, that arise during the process of measurement 
by an instrument, another type of error can affect a measurement without being, per se, a 
measurement error. This is the case of induced electrical noise, or induced voltage noise. These 
noise terms arise when an electrical output signal generated by sensors or transducers are 
corrupted by induced currents. (Morris & Langari, 2016).  
The principal induced voltage noise action modes are differential and common. Differential 
noise mode arise inside a circuit when the noise source acts in serie with the voltage output of 
a sensor or a transductor, these can cause significant errors in the measured output. The 
magnitude of corruption from a differential noise is called signal-to-noise ratio defined as: 
𝑆𝑁𝑅ௗ஻ = 20 logଵ଴ ቀ
୚ೞ
୚೙
ቁ.                (4.1) 
where Vs is the mean voltage of the signal and Vn is the mean voltage of the noise. 
In the case of AC differential mode noise voltages, the root-mean-squared value of the voltage 
is used in place of Vn (Morris and Langari, 2016). Common mode noise voltages are less 
impacting, because they usually affect both side of the signal circuit modifiying both outputs 
by the same level, thus having no effect on the level of output signal, but they must still be 
considered as sometimes common mode noise voltage can generate a differential mode noise 
voltages. Induced voltages can arise both inside the measurement circuit and during the 
transmission of the signal. The most common source of noise during the transmission of the 
signal is the proximity to other electric appliances, power sources or radio signals. The most 
common sources of noise voltages inside a measurement circuit include thermoelectric 
potentials, shot noise and potentials due to electrochemical action (Morris and Langari,2016). 
Although much can be made to enhance measurement systems in order to better process error 
sources, either random, systematic or due to noise voltages, these uncertainties can never be 
removed altogether prompting all the research that have been done in the area.   
 
4.1.2 Impact of measurement errors on process modeling 
As discussed in the previous section, many sources of measurement error exist. With the ever 
increasing importance placed on modeling by the regulatory agencies and the call for 
accurateness and reliability of those models (see chapter §1), it is necessary to account for the 
effect of measurement error at the calibration stage of any model adopted to assist a DS 
identification exercise. 
 
44 Chapter 4 
 
Measurement error in the variables of a model can potentially have three notable effects 
(Carroll et al, 2006): 
 it may cause a bias in the parameter estimation for statistical models; 
 it may lead to a loss of power, sometimes profound, for detecting interesting 
relationship among variables; 
 it may mask the main features of the data, making graphical model analysis difficult. 
While most of the work in literature is focused on the first two effect, relatively little work has 
been done to account for the third effect. To understand the effect of measurement error, a brief 
example adapted from Carroll et al, (2006) is presented. 
Let x be an error prone variable uniformly distributed on an interval [-π, π]. Suppose that y is a 
response with a mean of sin (2x) with a small standard deviation of 0,1. In Figure 4.1, the blue 
circles represent 628 draws from the variable x measured without error. Now suppose that 
instead of detecting the true variable x it is only possible, due to the measurement system in 
use, to observe w, a variable with mean equal to x and standard deviation of 0.8.   
It is clear that the sinusoidal response is not readily visible in the red diamonds, the error has 
hidden the key feature of the data and someone trying to construct a basic regression from w 
would probably not use a sinusoidal interpolating function. It is also possible to note the loss 
Figure 4.7: Comparison between a true quantity and a measured one, observations have 
mean equal to sin (2x) and small standard deviation, blue circle are shown at the right 
location x, while red diamonds are shown at a location w measured with error; w~N (x ,0.8). 
(Adapted from Carroll et al, 2006) 
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of predictive power, the variability of (x, y) around the sinusoidal function is lower than any 
curve that could be fitted from (w, y).   
In presence of variables measured with error it is not possible to calculate the parameters of the 
regression of y on x, since x is not observed. The usual goal of measurement error modelling 
then is to build a bridge that will permit to compute the parameters of y on x starting from w. 
This goal is not as straightforward as it seems and if the values of w were to be used instead of 
x, obvious errors would arise (Carroll et al, 2006).  
The effect on measurement error on parameter estimation has been extensively studied in the 
literature (Abramowitz et al., 2005) (Allegrini et al, 2018) (Aoki et al, 2001) (Mallick et al., 
2002). In particular, in the context of regression analysis, it has been proved that the 
measurement error, even if a simple additive error, causes the parameters of a regression of y 
on x to be biased towards zero: 
B∗ = B(ఙೣ
ఙೢ
).                (4.2) 
Equation (4.2) is valid only for univariate x. For the regression of a multivariate matrix of 
variables X on a vector of responses y the regression parameters B will be biased accordingly 
to the following equation (Carroll et al, 2006): 
 𝐁∗ = (𝚺𝑿𝑿 + 𝚺𝑼𝑼)ିଵ[(𝚺𝑿𝑿)𝐁 + 𝚺𝑼𝑬],                  (4.3) 
where Σab stands for the covariance between a and b, U is the matrix containing the 
measurement error of X and E is the matrix of the residuals as in Equation (2.36). 
The simplest type of error model is the classical error model, expressed as: 
𝑤௜௝ = 𝐱௜ + ∆x௜௝.                (4.4) 
In the classical error model, the true variable is measured with additive error, usually with 
constant standard deviation (i.e.: unchanging in subsequent repeated measurement). 
In this model, the observed quantity w is an unbiased measure of the true value x, and as such 
it must have zero mean: 
E൫𝑤௜௝ห𝑥௜൯ = 0 .                  (4.5) 
In the classical measurement error model, the error can be heteroscedastic or homoscedastic, 
which means that the error variance could or could not depend on the measured quantity. In 
the case of homoscedasticity of the error, the ΔX is independent and identically distributed with 
a normal distribution, that is: 
𝚫𝐗 ~ N(0, 𝚺௱௫).                (4.6) 
In the case of heteroscedasticity, the variance of the error depends on the value of another 
variable.  In this case, the variance of the error term could be, e.g.: 
𝚫𝐗 ~ N(0, α଴ + αଵ𝑓(𝐗) + αଶ𝑓(𝐙)),                  (4.7) 
where Z is a matrix of covariates of X. 
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Another error model that could be of importance in industrial applications is the Berkson error 
model. With this model, the measured variable is in some way approximated, i.e.: 
𝑥௜௝ = 𝐰௜ + 𝑢௜௝,                  (4.8) 
with wi an unbiased measured of xi; 
E൫𝑢௜௝ห𝐰𝒊൯ = 0,                  (4.9) 
information of the actual variation of the true variable xi is lost in the measurement. This type 
of error is common when a fixed value is assumed for the x variable (e.g.: a fixed minimum 
distance between rolls in a roll compactor, or a fixed value of weight for a powder fed in 
different sieve tray analysis). When measurement are taken continuously it can be assumed that 
the errors are independent and identically distributed, clearly this assumption has to be verified. 
A simple procedure that can be used to do so is the visual inspection of the quantile-quantile 
plot of the differences between the measurements. A Quantile-Quantile plot is a plot of points 
whose coordinate are the ordered points of the dataset versus the expected value of the 
distribution at the same quantile. If the plot is linear, the sample likely comes from the 
distribution used to compute the other quantiles (Everitt and Skrondal, 2010). While applied to 
the whole dataset this test would give no indication of the distribution of the errors applying it 
to the difference between replicates of the same measurement can give an idea of the 
Figure 4.2: Quantile-Quantile plot of one of the variable used for case study #2 in chapter 
§5, as it can be seen the intra variable difference appears to be normally distributed 
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characteristics of the error structure. While it provides a quick visual way to assess normality 
of a distribution the use of a q-q plot has its downsides as it is reported that it can lead to false 
assumption of adherence to a normal distribution for samples that are distributed according to 
distributions that have similar shapes. Non-normality is evident only in the presence of heavier-
than-Gaussian tails (Carroll et al, 2006), such as those of a lognormal or a pareto distribution.  
The models presented in Equations (4.4) and (4.8) are the most simple models for the modelling 
of errors, but most of the assumption at the base of their formulation hold in industrial cases if 
the measurement systems are accurately designed.  
Other error models include the “general classical measurement model” or the “regression 
calibration model” that are generalization of the classical and Berkson models already 
presented, and models tuned for specific applications, where the structure and the nature of the 
error term is problem-specific and well-understood and can be modelled extensively, e.g.: the 
model to correlate the estimated glomerular filtration rate, found via correlation equations, to 
the actual glomerular filtration rate, used to predict the progression of coronary kidney disease. 
It is worth noting that outside the statistical and medical literature most applied models are 
focussed on linear, univariate application. 
4.2 Modeling measurement error for Bayesian DS determination 
In the following, a procedure to account for measurement uncertainty in the Bayesian DS 
determination methodology proposed in the previous Chapter is presented. 
First, the problem statement will be presented. Secondly, the mathematical formulation of the 
proposed approach will be disclaimed. Lastly, the step-by-step methodology will be presented 
and discussed with an illustrative case study. 
4.2.1 Problem statement 
The methodology will be discussed for the multivariate linear regression model of Eq.  (3.8):  
𝐘 = 𝐖𝐁 + 𝐄௦               (4.10) 
where W now substitutes X as it is assumed that X is measured with error.  
It has been reported in chapter §4.1.1 that measurement error could be of random and 
systematic nature or due to induced noise voltages. Herein only random errors are considered, 
since in most industrial cases continuous measurements taken with well-maintained and well-
designed measurement systems, remove all systematic measurement errors and induced 
electrical noise up to the instrument accuracy. For this reason the measured quantity, W, is 
assumed to be an unbiased measure for the values of X.  
The model used to incorporate the measurement error is the classical measurement error model 
of Equation (4.4).  
 
48 Chapter 4 
 
By plugging in Equation (4.4), into Equation (4.10), Equation (4.10) can be rewritten as: 
𝐘 = (𝐗 + 𝚫𝐗)𝐁 + 𝐄௦.              (4.11) 
Equation (4.11) can be rearranged to obtain an expression similar to the one of Equation (3.8), 
obtaining: of,  
𝐘 =  𝐗𝐁 +  𝐄௠  +  𝐄௦  ,               (4.12) 
where Em is 𝚫𝐗 × 𝐁, which is the error term related to the measurement noise.  
Let Etot be the sum of the residuals due to the measurement noise and the structural model error, 
i.e.: 
𝐄௧௢௧ = 𝐄௠ + 𝐄௦.               (4.13) 
The model parameters are assumed to be normally distributed with mean Bഥ and standard 
deviation equal to Σtot, i.e.: 
𝐁~N(𝐁,ഥ 𝚺௧௢௧).               (4.14)  
It is important to note that this approach is different from the one used in classical Bayesian 
error modelling. In classical Bayesian error modelling, which is the hierarchical modelling, 
another model would be necessary as exposure model for the true variable X (Carroll et al, 
2006), in addition to the necessity to compute an increased number of parameters.  Other than 
B, and the components of Σtot, most models ask for the Bayesian computation of at least 
structural error, measurement error and true variable standard deviation and means, in addition 
to other hyperparameters that could be necessary to express the final model (Carroll et al, 
2006).  
In order to perform a combined Bayesian calibration of 𝐁 and 𝐄𝑡𝑜𝑡 it is necessary to: 
 find a pdf for Etot, given the pdfs of Em and Es. In other terms, the problems consists of 
determining the pdf for a summation of two multivariate Gaussian distributions.  
 find a pdf for Em, given the pdfs of 𝚫𝐗 and 𝐁. In other terms, the problems consists of 
determining the pdf for a product of two multivariate Gaussian distributions. 
A brief discussion on how to solve these two issued is described in the following. 
4.2.2 Summation of two multivariate Gaussian distributions 
The probability distribution of a sum of distributions is the convolution between the individual 
distributions (Bromley, 2014). The convolution theorem is used to this purpose: 
P௙⊗௚(𝐱) = Fିଵ[F(𝑓(𝐱))F(𝑔(𝐱))]  =  𝑓(𝒙)  ⊗  𝑔(𝒙)              (4.15) 
where F is the Fourier transform, F-1 denotes the inverse Fourier transform and ⊗ is the 
convolution symbol, while f(x) and g(x) are two probability density functions. The Fourier 
transform of f(x) is defined as: 
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F൫𝑓(𝐱)൯ =  ௘
షమಘ೔ೖ𝛍೑
√ଶ஠𝚺೑
∫ 𝑒
ି 𝐱
ᇲమ
మ𝚺೑ 𝑒ିଶ஠௜ 𝐱ᇲ∞ି∞ d𝐱
′               (4.16)  
with x’=x-μf mean-centred value of x. 
Euler’s formula can then be applied to split the integral in x’: 
 F൫𝑓(𝐱)൯ =  ௘
షమಘ೔ೖ𝛍೑
ඥଶ஠𝚺೑
∫ 𝑒
ି 𝐱
ᇲమ
మ𝚺೑∞
ି∞ [cos (2π𝑘𝐱
ᇱ − 𝑖sin(2π𝑘𝐱ᇱ)]d𝐱′,               (4.17) 
The second part of the formula contains the integral from -∞ to ∞ of the sine function. This 
function is odd, so its integral in a space of equal positive and negative spanning will be zero. 
In virtue of this, it can be crossed out leaving only the cosine term. 
The remaining integral can be solved obtaining: 
F൫𝑓(𝐱)൯ = 𝑒ିଶ஠௜௞𝛍೑𝑒ିଶ஠
మ௞మ𝚺೑ .                (4.18) 
The same applies for g(x) giving a similar result. Multiplying the two Fourier transform it is 
possible to write: 
F൫𝑓(𝐱)൯F൫𝑔(𝐱)൯ = 𝑒ିଶ஠௜௞𝛍೑𝑒ିଶ஠
మ௞మ𝚺೑ 𝑒ିଶ஠௜௞𝛍೒𝑒ିଶ஠మ௞మ𝚺೒ ,               (4.19) 
F൫𝑓(𝐱)൯F൫𝑔(𝐱)൯ = 𝑒ିଶ஠௜௞(𝛍೑ା𝛍೒)𝑒ିଶ஠మ௞మ(𝚺೒ ା𝚺೒ ),               (4.20) 
Since these Fourier transforms are invertible, Equation (4.15) can be solved to determine that 
the resulting probability density function will have a mean equal to the sum of the two means 
and a standard deviation equal to the sum of the individual standard deviations: 
Fିଵ[F(𝑓(𝐱))F(𝑔(𝐱))]  = ଵ
ଶ஠
೙
మට|(𝚺೑ ା𝚺೒ )|
𝑒ି
భ
మ(𝐱ି(𝛍೑ା𝛍೒))
𝐓(𝚺೑ ା𝚺೒ )షభ(𝐱ି(𝛍೑ା𝛍೒))       (4.21) 
where n is the dimensionality of the PDFs. 
𝛍௦௨௠ = ∑ 𝛍௜ூ௜ୀଵ                (4.22) 
𝚺௦௨௠ = ∑ 𝚺௜ூ௜ୀଵ                (4.23) 
From Equations 4.22 and 4.23 it is the possible to see that the sum of probability density 
functions (PDFs) via convolution is a PDF with mean equal to the sum of the mean and 
covariance matrix equal to the sum of the covariance matrices. 
4.2.3 Multiplication of two multivariate Gaussian distributions 
It is possible to define a canonical parametrization for a normal PDF that can be linked to the 
usual moments parametrization by: 
𝚲 = 𝚺ିଵ,                (4.24) 
𝛈 = 𝚺ିଵ𝛍,                (4.25) 
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Where η is the information vector, Λ is Fisher information matrix, μ is the n-vector of the 
means and Σ is the n-by-n covariance matrix.  
Using the transformation of Equations 4.24 and 4.25 a PDF can be written in canonical 
notation, i.e.: 
P(𝐱) = e[𝛂ା𝛈
౐𝐱ିభమ𝐱
౐𝚲𝐱],                (4.26) 
where the quantity α is a scale factor: 
𝛂 =  −(𝑛 log(2π) − log |𝚲| +  𝛈୘𝚲ିଵ𝛈)                (4.27) 
and n is the dimensionality of x.  
Using the canonical notation is possible to compute the multiplication of the functions as a 
summation of the single PDFs, i.e.: 
∏ P௜(𝐱)ூ௜ୀଵ = exp [ 𝛂௜ୀଵ…ூ + (∑ 𝛈௜ூ௜ୀଵ )୘𝐱 − 
ଵ
ଶ
 𝐱୘(∑ 𝚲௜ூ௜ୀଵ )𝐱],                                 (4.28) 
with 
𝛂௜ୀଵ…ூ = −In( log(2π) − ∑ log |𝚲|௜ூ௜ୀଵ +  ∑ 𝛈௜୘𝚲௜ିଵ𝛈௜ூ௜ୀଵ ).                                      (4.29) 
It is possible to transform Equation (4.29) to a form in principle equal to the one of Equation 
(4.26) multiplied by a scale factor by adding and subtracting αI, giving: 
∏ P௜(𝐱) = exp[𝛂௜ୀଵ…ூ − 𝛂ூ] exp[ூ௜ୀଵ 𝛂ூ + (𝛈ூ)୘𝐱 −  
ଵ
ଶ
 𝐱୘(𝚲ூ)𝐱]               (4.30) 
where the total information vector is: 
𝛈ூ = ∑ 𝛈௜ூ௜ୀଵ ,               (4.31) 
and the total Fisher information matrix is: 
𝚲ூ = ∑ 𝚲௜ூ௜ୀଵ .               (4.32) 
The total scale factor is given by: 
𝛂ூ = −(𝑛 log(2π) − log |𝚲|ூ + 𝛈ூ୘𝚲ூିଵ𝛈ூ ).                (4.33) 
The resulting function is still a Gaussian PDF over x. Equations (4.31) and (4.32) are then 
transformed back to moments notation using Equations (4.24) and (4.25). The following 
formulae for the mean and the standard deviation of the product of PDFs are obtained, i.e.:  
𝛍௣௥௢ௗ = 𝚺௣௥௢ௗିଵ (∑ 𝚺௜ூ௜ୀଵ 𝛍௜)                (4.34) 
𝚺௣௥௢ௗ = (∑ 𝚺௜ିଵ)ூ௜ୀଵ
ିଵ                (4.35) 
where μprod is the mean of the product of two or more PDFs and Σprod is their covariance matrix 
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4.3 Proposed methodology 
Based on the mathematical background described above, step d) of the methodology reported 
in chapter §3.3 for the Bayesian DS determination has been extended to account for the 
measurement errors in the calibration dataset. Applying the modelling strategy of the previous 
section is now possible to combine the results of Equations (4.22) and (4.23) with those of 
Equations (4.34) and (4.35) to obtain a method of applying Equation (4.13) as the model linking 
CPP and material attributes to CQAs. 
The new proposed methodology is composed of 7 steps and is described as follows: 
1. Assess the normality of the error distribution. In this study a q-q plot has been used as 
shown in Figure 4.2. To assess normality of the measurement error with a q-q plot take 
a sufficiently representative subset of each variable in the dataset, xj* ⊆ xj for all 
variables j, compute the differences between all variables in the subset, the proposed 
way is to use the nchoosek.m command in MATLAB to compute the possible 
combination and subtract according to these combinations, use the result of the 
subtraction with the MATLAB qqplot.m routine and assess the results. This can be done 
graphically or automated with a script assessing deviation from the normal distribution 
via distance from the normal quantile line. 
2. PLS model calibration 
3. Knowledge space discretisation 
4. Space filling sampling within the KS to obtain a representative number of points  
5. Use a two-step algorithm for generating a prior for Em. The first step of the algorithm 
is a singular value decomposition of the error of ΔX to obtain the best rank-K 
approximation, where K is the number of variables in Y. The goodness of this 
approximation is assessed with an “eigenvalue greater than one” criteria. The second 
step is setting an objective function in order to find a Σm that satisfies this system   
𝚺௧௢௧ = 𝚺௦ + 𝚺௠,              (4.36)  
𝚺௠ = (𝚺𝜟𝑿ିଵ + 𝚺௧௢௧ିଵ )ିଵ.               (4.37) 
6. a) Generation of a new candidate for B 
      b) Generation of a new candidate for Σs 
      c) At this step a new candidate is generated for Σm. This new candidate is generated 
from and inverse-Wishart distribution where the scale matrix parameter of the 
distribution is modified to account for the presence of Σs and its probability is then 
assessed with Equation (3.14), a Metropolis Hastings is then used to decide to keep the 
sample or discard it as per procedure explained in chapter §2.3.  Σtot is computed at 
every iteration using Equation (4.36) 
d) Generate a new candidate for y 
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7. Computation of p = Pr(yl ∊ AR|xl,X,Y) 
 
This methodology is illustrated in Figure 4.3. 
6) Determination of the posterior predictive 
distribution of the model outputs for the point xl
Start
2) PLS model calibration
3) Knowledge space 
discretization (Na  samples)
4) Space-filling sampling 
within the KS (Ns samples:  
xl , l=1,…,Ns) 
7) Computation of 
p = Pr(yl ∊ AR|xl,X,Y)
p ≥ θth
Yes No
The sample belongs 
to the Bayesian DS
The sample does not 
belong to the 
Bayesian DS
N < Ns
Stop
Yes
No
1) Measurement Error 
distribution conformance to 
normality assessed
5) Computation of a prior for 
the Σm
6.a) Generation of a 
new candidate for B
6.c) Generation of a 
new candidate for Σm
6.b) Generation of a 
new candidate for  Σs
6.d) Generation of a 
new candidate for y
Figura 4.3: Flowchart for the proposed methodology for the incorporation of uncertainty 
derived from measurement error in a Bayesian DS determination exercise, parts in red are 
modification to the original methodology proposed by Bano et al., (2018) 
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An illustrative example of the procedure will now follow. The methodology will be thoroughly 
explained with exemplification of the crucial passages. 
4.3.1 Applied methodology: an illustrative example 
This illustrative exampled is focussed on the calculation of the posterior predictive distribution 
for  y given an x not belonging to the original dataset and on the differences between the method 
proposed by Bano et al.,(2018) and the modifications proposed in this thesis.  
One hundred random variables have been generated using MATLAB to sample from 
determined distributions. 
The distributions are as follows: 
Figure 4.3: Assessment of normality of the error of measurement of the variables X in 
Equation (4.34) using the q-q plot method (Carroll et al., 2006) 
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ቐ
𝐱𝟏~N(−0.007043, 1.15915)
𝐱𝟐~N(−0.095056, 1.14323)
𝐱𝟑~N(0.04298, 0.76840)     
                (4.34) 
The response has been constructed via MATLAB as:  
൜𝐲ଵ = 𝐱ଵ − 5𝐱ଶ + 5𝐱ଷ   𝐲ଶ = 2𝐱ଵ − 3𝐱ଶ + 3𝐱ଷ
              (4.35) 
The normality of the distribution of errors has been assessed from the inspection of the q-q 
plots shown in Figure 4.3. 
A value for the measurement noise is usually known, given by the investigator that supplies 
the data. Since data for this case study have been simulated a value for the first guess of the 
measurement noise has been set as a percentage of the standard deviation of the mean 
calculated starting from a random point in the dataset adding a random point at the time up to 
the whole dataset. The tentative first guess is: 
𝚺𝜟𝑿 = 0.1 × ൥
0.1086 0 0
0 0.1715 0
0 0 0.1352
൩              (4.36) 
The values in Equation (4.36) are less than one percent of the simulated dataset variation, a 
diminutive measurement error.  
A singular value decomposition (SVD) of the error is now carried out; incidentally, for 
Equation (4.36) and similar completely independent errors the SVD is just the diagonal values 
ordered by magnitude. The SVD decomposition is used to approximate this [3×3] matrix to a 
[2×2] matrix (the number of variable in the response dataset Y) to be used in the recursive 
calculation of step b) in chapter §4.3. 
After the approximation, the value of the first discarded eigenvalue is used to assess the 
approximation. After the approximation an objective function has been set using Equation 
(4.33) and optimized via successive minimizations. The prior parameter for the Σs of the model 
is I2 the two dimensional identity matrix. The result of the minimizations is the prior that will 
be used in the subsequent steps of the methodology, i.e.: 
Σெబ ≅ ቂ
0.1199 0
0 0.0980ቃ              (4.37) 
Where the approximation sign has been used to imply that the value reported are truncated and 
not the ones used in the iteration.  This problem is a subset of the whole methodology presented 
in chapter §3.3 if the point at which the PPD is calculated is thought as one of the Ns samples. 
Once that a prior is obtained it is possible to proceed with step c) of the methodology proposed 
in the previous section. At each iteration, once all other parameters have been updated a new 
candidate is generated for Σm with the MATLAB iwishrnd.m function and assessed with 
Equation (3.14) reported again here, i.e.: 
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ℒ(𝚺௦|υ, 𝐆, data) =
𝚺ೞ
ഔష೙షభ
మ
𝐆
ഔ
మ
eቂି
భ
మ୲୰ୟୡୣ(𝐆
షభ𝚺ೞቃ.              (4.38) 
While the same υ is used, in this step Gm is different from the one used in the original 
methodology, Gs, calculated as:  
𝐆௦ = ቂ
𝜐 0
0 𝜐ቃ + [𝐲 − 𝐁𝐱]
୘[𝐲 − 𝐁𝐱].              (4.39) 
In the proposed methodology the accepted value of Σs at the current step is used to control the 
dimension of the proposed Σm  
𝐆௠ = ቂ
𝜐 0
0 𝜐ቃ + [𝐲 − 𝐁𝐱]
୘[𝐲 − 𝐁𝐱] − 𝚺௦              (4.40) 
The resulting matrix, assessed at the ninety thousandth iteration is:  
𝚺௧௢௧ ≅ ቈ𝚺௠ ≅ ቂ
 0.0827 −0.0643
−0.0643 0.0840 ቃ + 𝚺௦ ≅ ቂ
0.0231 0.0165
0.0165 0.0247ቃ቉.              (4.41) 
While the matrix sigma calculated with the original methodology at the same step is: 
𝚺௦ ≅ ቂ
0.0177 −0.0118
−0.0118 0.0189 ቃ.              (4.42) 
The resulting PPDs are presented in Figures 4.4 and 4.5. The original methodology resulted in 
a normal distribution with: 
൜𝐲ଵ~N
(0.9924, 8.59529); 
𝐲ଶ~N(2.080, 9.4363),      
              (4.43) 
With expected values calculated by direct substitution of (1, 2). 
The proposed methodology resulted in two normal distributions with similar mean parameters 
but higher standard deviation, i.e.: 
൜𝐲ଵ~N
(1.097, 9.8326);  
𝐲ଶ~N(2.118, 10.9158).
              (4.44)   
with the same expected values. 
In this example the applied methodology to incorporate a method for accounting for the 
measurement error in the Bayesian DS determination exercise has been shown with in depth 
explanation of the necessary steps. It is possible, from the inspection of Figures (4.5) and (4.4), 
to see that the PPD computed with the proposed methodology has greater standard deviation. 
This visible added uncertainty is due to the incorporation of the measurement error. 
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This result is replicated for all the other points of the discretized KS, and the overall effect is a 
shrinkage of the resulting DS. Results of the full methodology applied to mathematical and 
industrial cases will be reported in the next chapter. 
Figure 4.4: PPD of the value of Y calculated with the original methodology the predicted 
values are very close to the expected outcome. The actual values are reported in Equation 
(4.43) 
Figure 4.5: Calculated PPD of the values of Y calculated with the modified 
methodology; the mean is still very close to the expected outcome. The standard 
deviation is visibly bigger. The actual values are reported in Equation (4.44) 
  
 
Chapter 5 
Case studies 
 
In this Chapter, three case studies will be presented showing the completed DS determination 
exercise and comparing the obtained results to those coming from the application of the original 
methodology. 
5.1 Case Studies 
Three further examples of the methodology proposed in chapter §4.3 are presented herein. A 
mathematical case, chosen for its nonlinearity and correlation, one of the weaknesses of 
regression methods. An industrial case from a sieve tray analysis of two different API 
formulations. Lastly, industrial data are analysed in a DS building exercise targeting the 
compactability ratio of a wet granulation process.  
5.1.1 Case #1: Mathematical Example 
A highly correlated, nonlinear dataset is used as the first case study. This dataset is generated 
as reported in an article by Facco et al., (2015). The dataset is composed of one hundred 
observations, each of five parameters that simulate a historical dataset. The input calibration 
matrix M [100 × 5] collects both the dependant and the independent inputs.  The dependant 
input called m1 and m2 to maintain the convention of the original article are sampled from two 
normal distributions, i.e.: 
𝐦ଵ~ N(41.73, 16.07),                  (5.1) 
𝐦ଶ~ N(11.13, 2.97).                  (5.2) 
While the dependent variables are defined as follows: 
𝐦ଷ = 𝐦ଵଶ                  (5.3) 
𝐦ସ = 𝐦ଶଶ                  (5.4) 
 
58 Chapter 5 
 
𝐦ହ = 𝐦ଵ𝐦ଶ                  (5.5) 
The calibration response dataset is generated by a mathematical formulation, i.e.: 
𝐲 = 𝑘଴ + 𝑘ଵ𝐦ଵ + 𝑘ଶ𝐦ଶ + 𝑘ଷ𝐦ଷ + 𝑘ସ𝐦ସ + 𝑘ହ𝐦ହ                  (5.6) 
Where the parameter vector is equal to: 
𝒌 = [𝑘଴ = −21.0, 𝑘ଵ = 4.3, 𝑘ଶ = 0.022, 𝑘ଷ = −0.0064, 𝑘ସ = 1.1, 𝑘ହ = −0.12]  (5.7) 
Values have been selected with MATLAB, via a pseudorandom number generator based on 
Mersenne twister with seed zero. 
The characterisation of the dataset is reported in Table 5.1 
Table 5.1: Case study #1: Characterization of the input and output dataset 
Variable Mean Standard deviation 
u1 43.708 18.68 
u2 10.91 2.99 
u3 2255.83 1801.50 
u4 127.94 67.79 
u5 481.20 265.68 
y 235.74 76.80 
 
5.1.2 Case #2 Sieve analysis data 
A historical dataset on a wet granulation process has been analysed with the proposed 
methodology to identify a probabilistic design space for wet granulation. The original dataset 
is composed of 38 repetitions of thirteen variables. A subset of the original dataset has been 
used. The subset is M [21 × 7] and is composed of 21 observations at different conditions. The 
scale of the experiment has been used to create this subset and is constant during the analysis. 
The variables to investigate have been chosen based on similarity with known systems. 
A summary of the used variables is available in Table 5.2. The sieve tray analysis has been 
processed to obtain the sample d50 and d90; the d50 has been used as a target for the present 
analysis.  
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Table 3.1: Case study #2: list of the input and response variables. 
ID Variable name Units Symbol 
Inputs 
1 Tip speed [m/s] ut 
2 Conveying rate [kg/hr] Fc 
3 PFN [-] PFN 
4 Froude number [-] Fr 
5 Torque data [N/m] τ 
6 Power [W] W 
7 SME [J/g] SME 
Response 
R1 Median particle size [mm] d50 
R2 90-th percentile [mm] d90 
5.1.3 Case 3# Wet granulation experimental data 
This case study considered the exercise of constructing a probabilistic design space for a new 
high-shear wet granulation process. The experiment data used are available from the work of 
Oka et al., (2015). The historical dataset is composed of 27 observations of three input 
characteristics and one response and is based on a full factorial DoE (3 × 3 × 3). For the design 
space construction exercise three input variables are considered, and their impact on the particle 
size distribution of the granulate has been studied. In Table 5.3 a summary of the outputs and 
inputs is presented. 
Table 5.3: Case study#3: list of the input and response variables (data from 
(Oka et al., 2015)) 
ID Variable name Units Symbol 
Inputs 
1 Liquid to solid ratio [-] L/S 
2 Impeller speed [rpm] νimp 
3 Wet massing time [min] τwet 
Response 
R1 Median particle size  [μm] d50 
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5.1.4 Wet granulation: process description 
Wet Granulation is a particle size enlargement process employed in a variety of industries to 
convert fine powders into granules. It involves the use of a liquid binder for particle 
agglomeration and consolidation. The liquid binder is distributed on the powdered particles 
while a mixer blends the powder. The wetted particles will form nuclei that are then deformed 
and densified during the collisions with the vessel wall, the agitator’s blades or other particles. 
The densification process will force the liquid out of the particles allowing coalescence and 
binding with other particles to form larger aggregate. Breakage also occurs during the process 
when the collision force exceeds a critical value. In Figure 5.1 a schematic representation of 
the steps of wet granulation are presented.  
In the first steps of the wet granulation process, wetting and nucleation, liquid/solid ratio and 
powder wettability play a crucial role. These parameters have been linked to a broader 
distribution of nuclei size (Lee, 2012), that, in turn, leads to wider distribution of granule size 
in the final product, as the process usually retains some sort of “memory” of this step (Hapgood 
et al., 2007). At this stage, nucleation occurs, usually in one of two primary modes depending 
on the relative dimension of the droplet used to wet the powder blend and the principal particles 
of the blend. Either the droplets are smaller and distribute on the surface, allowing the wet 
particle to coalesce with other dry particles, giving a more agglomerated nucleus, or the powder 
is smaller, and immersion mode nucleation occurs, characterised by nuclei of more compact 
nature (Lee, 2012). In this stage mixing and thus impeller tip speed has a critical role; one of 
the most beneficial regimes of operation is the Mechanical dispersion regime, thus defined in 
Hapgood et al., (2003), where powder mixing dominates the liquid dispersion, that depends on 
the mechanical mixing and agitations only. In the mechanical dispersion regime, nuclei will 
have a uniform size distribution.  
After wetting and nucleation, a further step called granule growth and consolidation takes 
place. This step is of crucial importance as the final granule properties (size and density) will 
be decided at this stage. The particle growth is influenced chiefly by the wet massing time. The 
Figure 5.1: Schematic process of a wet granulation  (Kumar, et al., 2014) 
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two most common types of granule growth that generally occur are steady growth and 
induction growth. Steady growth is described as when the rate of growth is approximately 
constant. Induction type of growth is described as when there is an induction time with no 
growth followed by rapid growth (Lee, 2012). Consolidation takes place due to compressive 
and shear forces pushing the particles together, this reduces size and density of the resulting 
particle and influences its porosity. Consolidation influences the growth process, particularly 
on induced growth, and depends primarily on the solid to liquid ratio (Tardos et al., 1997). 
Granules breakage and attrition is the last stage in the wet granulation process. Granules 
breakage refers to the phenomena where wet granules break due to high shear forces exhibited 
in granulators. Breakage of wet granules can control the maximum and final granules sizes, so 
a careful balance needs to be struck between the need to agitate the powder blend to obtain 
mechanical dispersion regime and the added width in the final granule dispersion. 
5.2 Results and discussion 
In this section results of the DS building exercise for the three case studies presented in the 
previous section are presented with comparison to the ones obtained with the original 
methodology will be made. For each case study apart from the first two scenarios are simulated, 
one with highly noisy measurement, with a variance of the noise of 10% of the mean and a 
normal error scenario with variance of the noise of 1% of the sample mean. 
5.2.1 Results for Case study #1 
The assessment of the adherence to the normal distribution of the measurement error is carried 
out with a q q-plot. A PLS model is then built using the calibration dataset, the number of latent 
variables to retain in the test is evaluated using an eigenvalue greater than one rule. A number 
A=2 of latent variables is chosen explaining 95.1% of the total variation on M. Note that since 
A > rank(y), a null space exists. The problem of including the uncertainty derived from noisy 
measurements on a DS building exercise with ydes=283 is addressed, with an acceptance 
probability threshold of 90%. The ability of the proposed methodology to include the 
measurement error is tested. The real DS of the process is then derived from first principles, in 
this case, Equation (5.6), and is reported as a black line in Figure (5.3). In the original article 
by Facco et al., (2015) interesting remarks on the representativeness of the PLS in the case that 
the input is strongly nonlinear are reported. A prior has been generated for the analysis, in this 
case, a value close to a percentage of the mean has been used in the procedure proposed in 
chapter §4.3 to compute a prior for the measurement error.  
In the case of Figure (5.3) the input matrix is: 
𝚺𝜟𝑿 = diag [5 1 315 55 130]       (5.8) 
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Where diag (n) means a matrix with the term n as the diagonal and zero in all off-diagonal 
terms. The used methodology resulted in a value for ΣM, i.e.: 
𝚺𝒎 ≈ 0.2803.                  (5.9) 
In both images the points included in the DS are reported as green diamonds, while the points 
below the threshold are reported as red diamonds. A thick blue line delimits the boundary of 
the knowledge space and the calibration dataset is reported as blue circles. In Figure (5.3) the 
reduced DS is bounded by a thin blue line for a better visualisation. The thin blue line is 
computed using the MATLAB boundary command using the “shrink-factor” option to control 
the tightness of the boundary. 
5.2.2 Results for Case study #2 
The assessment of the normality of the measurement uncertainty distribution is carried out with 
a qq-plot. In this case study the problem at hand is the DS building exercise for a granulate 
with a median particle size of 0.4099 mm starting from historical data of a known process. The 
ability the proposed methodology to identify a subset of the original knowledge space within 
which the probability that the products will be on target or superior, while accounting for 
measurement error in the calibration dataset, is assessed. A probability of 90% is used as a 
threshold for acceptance. A PLS model is built using the calibration dataset, the number of 
latent variables to use is evaluated using an eigenvalue greater than one rule and a number A=2 
Figure 5.2: Case study#1; base case, the uncertainty linked to the error has not been 
accounted for and values near the edge could be below the required 90% assurance. The 
green diamonds are points with probability greater than the threshold, red 
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of latent variables is chosen explaining 82.24% of the total variation on M. A prior has been 
generated for the analysis, a percentage of the mean has been used in the procedure proposed 
in chapter §4.3 to compute a prior for the measurement error. 
In the case of Figure (5.5) the input matrix is: 
𝚺𝜟𝑿 = diag(0.1 ×  [𝝁𝑼])      (5.10) 
While for the case of Figure (5.6) the input matrix is: 
𝚺𝜟𝑿 = diag(0.01 ×  [µ𝑼])               (5.11) 
In both Equations (5.10) and (5.11) diag (n) means a matrix with n in the diagonal and zeros in 
the off-diagonal.  The resulting priors for ΣM are: 
 𝚺𝒎 ≈ 0.154,              (5.12) 
for the case of Equation (5.10) and: 
𝚺𝒎 ≈ 0.0175,                (5.13) 
for Equation (5.11). A point of known d50 equal to the desired one has been set apart and not 
used in the simulation to validate the results. This point is shown in Figure (5.4), (5.5) and (5.6) 
with a black square.  
Figure 5.3: Case study #1: A probabilistic DS constructed accounting for measurement 
uncertainty. Comparison with Figure (5.2) shows that the DS has shrunk as an effect of the 
lowered probability of attaining the required specification. The black line is the real DS 
calculated by first principles, the black circles are the calibration dataset, the thick blue line 
the knowledge space boundary and the thin blue line is a boundary computed with the 
MATLAB boundary command with a shrink-factor of 0.1.   
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Figure 5.4: Case study #2: Base case, the green diamond are the point whose probability of 
attaining the target d50 is equal or above 90%. The thick blue line is the knowledge space 
boundary. The black square is the validation point, a combination of input giving a d50 of 
0.4099 mm 
Figure 5.5: Case study #2: In this figure the green diamonds are point that have a probability 
of attaining a d50 of 0.4099 mm equal or greater than 90%. Red diamonds are rejected points 
and the black square is the validation point, with known d50 equal to the desired one. The 
assumed measurement error is equal to 10% of the mean. 
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5.2.3 Results for Case study #3 
The adherence of the measurement error to the normal distribution is assessed using a qq-plot. 
In this case study the problem at hand is the DS building exercise for a blend of active 
pharmaceutical ingredient (API) plus excipient starting from data available in the article from 
Oka et al., (2015). The desired output is a powder with a d50 of 1129 μm. A probability of 90% 
is used as a threshold for acceptance. A validation point has been identified with a response 
equal to the desired value; this point has been removed from the calibration dataset and used 
for confirmatory purposes. A PLS model is built using the calibration dataset, the number of 
latent variables to use is evaluated using an eigenvalue greater than one rule and a number A=2 
of latent variables is chosen explaining 66.7% of the total variation on M. This value is indeed 
low compared to the guidelines of chapter §3.4 and in fact the desired output, indicated in 
Figures (5.6), (5.7) and (5.8) with a black square, is closer to the edge of failure than in the 
other case studies, the simple structure of the data though make it possible to analyse the 
process nevertheless. Note that since A > rank(y), a null space exists.  
The difference in the shape of the knowledge space presented with this PLS model is due to 
the simple structure of the data and the fact that every variable has the same weight in the 
representation of the latent structure, as mentioned in chapter §2.2  
Figure 5.6: Case study #2: In this figure the green diamonds are point that have a probability 
of attaining a d50 of 0.4099 mm equal or greater than 90%. Red diamonds are rejected points 
and the black square is the validation point, with known d50 equal to the desired one. The 
assumed measurement error is equal to 1% of the mean.   
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A prior has been generated for the analysis, in this case, a percentage of the mean has been 
used in the procedure proposed in chapter §4.3 to compute a prior for the measurement error.  
In the case of Figure (5.7) the input matrix is: 
𝚺𝜟𝑿 ≈ ൥
0.0733 0 0
0 27.5 0
0 0 0.5
൩,      (5.14) 
While for the case of Figure (5.4) the input matrix is: 
𝚺𝜟𝑿 ≈ ൥
0.0073 0 0
0 2.75 0
0 0 0.05
൩.               (5.15) 
The resulting priors for ΣM are: 
 𝚺𝒎 ≈ 1.161,              (5.16) 
for the case of Equation (5.14) and: 
𝚺𝒎 ≈ 0.208,                (5.17) 
for Equation (5.15). 
Figure 5.6: Case study #3: Base case, the measurement error has not been considered. The 
green diamonds are points whose probability of attaining the target granule median size is 
equal to or greater than 90%. Red diamonds are points whose probability is lower and the 
thick blue line is the boundary of the knowledge space. The black square is the validation 
point whose median diameter equals the desired one. It stands close to the edge of failure 
due to poor representativeness of the PLS method for this system.  
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5.3 Final remarks 
As seen in the case studies the region of the accepted points is shrunk substantially. The 
shrinking is due to the increased degree of variance removed with the methodology proposed 
to the PPD of the y value. The selection algorithm at step five of the original methodology 
(chapter §3.3) and step seven of the proposed methodology (chapter §4.3), uses the integral of 
a portion of the area below the PDF to assess the probability of the calculated y to give the 
desired response.   
The values of the error have less impact than suspected, and verification of sensitivity of the 
methodology to the starting value of Σm in Equation (4.36) could be an interesting point of 
further investigation.  
 
 
 
 
Figure 5.7: Case study #3: Green diamonds are points with probability greater than 90% of 
giving a desired product, red ones have lower probability and the black square is the 
validation point. The thick blue line is the boundary to the knowledge space. In the 
establishment of this design space a measurement error equal to the ten percent of the mean 
has been assumed, as theorized the point is still inside the probabilistic boundaries 
notwithstanding the representativeness of the dataset being in the lower acceptable region.  
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The representativeness of the PLS retains its crucial importance from the original methodology, 
as seen in chapter §3.4. The smaller the amount of cumulative X-variability explained by the 
latent variables, the greater the error on the projection of the KS onto the latent space, and the 
worse the representation of the original input space by the latent space. In other words, there is 
a risk of not considering areas of the knowledge space that may be part of the design space.   
 
Figure 5.8: Case Study #3: Green diamonds are points with probability greater than 90% of 
giving a desired product, red ones have lower probability and the black square is the 
validation point. The thick blue line is the boundary to the knowledge space. In the 
establishment of this design space a measurement error equal to the one percent of the mean 
has been assumed, as theorized the point is still inside the probabilistic boundaries 
notwithstanding the representativeness of the dataset being in the lower acceptable region.   
  
 
Conclusions 
The objective of this Thesis was the incorporation of measurement uncertainty in the design 
space determination exercise for a new pharmaceutical product with a risk-based Bayesian 
posterior predictive approach, while simultaneously reducing the problem dimensionality using 
PLS modelling. The joint posterior predictive probability of each sampling point was obtained 
with a multivariate Bayesian linear regression model, and the probability that product quality 
will meet its specifications for the given point was computed. By performing this analysis for 
each of the sampling points of the historical knowledge space, the probabilistic (or Bayesian) 
DS of the product under investigation was determined. To compute the joint posterior 
predictive probability of each point a Bayesian framework was built. This framework is based 
on the one coded proposed in the study of Bano et al. (2018). 
Results are then shown in an intuitive way by two-dimensional latent structure projection. The 
obtained probabilistic DS represents a way to demonstrate (i.e., quantify) the level of 
“assurance of quality” the manufacturer can guarantee for a given product, as advocated by the 
pharmaceutical regulatory agencies. This “assurance of quality” is further refined with the 
addition of the possibility to account for the uncertainty derived from the measurement error 
(e.g.: noise) in the calibration input dataset. 
With respect to the original methodology, all the cases presented a lower number of accepted 
points, due to the additional source of uncertainty that has been included. Although all the case 
studies were conducted on a single vector of responses, the methodology is not limited to a 
one-dimensional output, despite the increase in computational complexity given that it could 
require more iterations per chain to converge.  
Some points of interest for future studies could be pointed out. For example, an optimization 
of the acceptance criterion for the MCMC, in order to get results in shorter time, this can be 
generalized to a further optimization of the whole code to run in online cloud computing or 
parallel computing. A second possible area of study is the addition of other error models, 
maintaining the general nature of the methodology the addition of further models should 
increase the assurance of quality and the possibility to have this design space determination 
software as customizable as possible. Another important area is the sensitivity analysis to 
variation to the initial value of the guess for the error of measurement Em covariance in 
Equation (4.36). While the effect of the error on the input matrix X has been thoroughly 
examined in the context of this Thesis, the effect of that value on the final DS could be of 
interest.  
  
  
List of symbols 
 
A = Number of selected latent variable (or principal components, 
depending on the context) 
B = Linear regression model parameters 
𝐁෡ெ௅ா = Maximum likelihood estimate of the parameters B 
cov (x) = Covariance of x 
c = PLS Y-weigth vector 
C* = PLS Y-weigth Matrix 
d50 = Median value of the particle size distribution [μm] or [mm] 
d90 = 90-th percentile of the particle size distribution [mm] 
𝑑௜ = Desirability function 
Droll = Roll diameter [m] 
E = Linear regression model residuals 
eija2  = Residual of variable j at observation i with a principal components    
Em = Measurement noise error matrix 
Es = Structural error matrix 
Etot = Total error matrix 
𝑓(𝒙)  ⊗  𝑔(𝒙) = Convolution between function f and function g 
F = PLS Y - residuals 
F = Fourier transform 
F-1 = Inverse Fourier transform 
F(A, I-A, α) = 95% percentile of the  F distribution with A degrees of freedom in 
the numerator    and (i-A) degrees of freedom in the denominator 
Froll  = Roller pressure force [kN] 
Fs = Spring-back factor [-] 
Gm = Scale matrix for the measurement covariance generation via Inverse 
Wishart distribution 
Gs = Scale matrix for the structural covariance generation via Inverse 
Wishart distribution 
𝑔(𝐲|𝐱, data) = Posterior predictive distribution of y given the observation x and the 
data 
 
 
   
   
   
   
   
I = Rows (observations) of the historical dataset 
J = Columns (variables) of the historical input dataset 
𝐉𝒕(𝛉∗ห𝛉𝒕ି𝟏) = Markov Chain jumping distribution 
K = Columns (variables) of the historical output dataset 
k = Compressibility factor 
ℒ(𝐁, 𝚺𝑩|𝐘) = Likelihood function 
L(P) = Lagrange function of P 
Li = Lower acceptable limit 
L/S = Liquid to solid ratio 
M = Input calibration matrix 
N(𝐁𝐗, 𝛔𝟐𝐈𝐍) = matrix-variate normal distribution with mean XB and covariance 
equal    to 𝝈𝟐𝑰𝑵 
Na = Total number of discretization samples 
Ns = Selected number of discretization samples 
P = PLS (PCA) model loading matrix 
pn = PLS model vector of the loadings for the n-th observation 
P(y|θ) = Probability of an occurrence y given the parameters θ 
P(𝐲 ∈ AR|𝐱, 𝐗, 𝐘) = Probability to be inside the acceptable range conditional on the vector 
x and the historical dataset X, Y 
Q = Y – scores matrix for the PLS 
Q2 = Goodness of fit statistic 
R2   = Goodness of prediction statistic 
Ra j
2
 =  Sum of square error for variable j with a principal components 
si2(A) = i-th singular value of matrix A 
sta2  = Score variance with respect of principal component a 
sroll = Roller width [m] 
T = PLS (PCA) model scores matrix 
tn = PLS model vector of the loadings for the n-th observation 
T2i = Hotellings’s T2 statistic for observation i 
T2lim = Confidence limit for the Hotelling’s T2 
Ti = Target state 
𝐓𝒕(𝛉𝒕|𝛉𝒕ି𝟏) = MCMC transitional distribution 
U = PLS Y-loadings 
 
 
 
Greek letters 
α  = Scale factor for the canonical form of the normal distribution 
γ EFR = Effective friction angle [rad] 
γ FR = Friction angle [rad] 
ΔX = Matrix of the random measurement error 
η = Information vector for the canonical form 
𝜃௧௛ = Probability threshold 
𝛉௚௜௕௕௦ = Gibbs sampler parameter vector 
Λ = Fisher information matrix for the canonical form 
λ = Lagrange multiplier 
μ = Mean  
νimp = Impeller speed [rpm] 
νroll = Roller speed [rpm] 
𝜎ොெ௅ா𝟐  = Maximum likelihood estimate of the variance 
Σ = Variance/covariance matrix 
Σab = Covariance between matrix A and B 
ΣΔX = Covariance of the measurement noise 
Σm = Covariance of the uncertainty due to measurement noise 
Σs = Covariance of the structural uncertainty 
Vn = Mean voltage of the noise 
Vs = Mean voltage of the signal 
w = PLS X-weight vector 
W = Matrix of noisy measurement of the true quantity x 
W* = PLS X-weight matrix 
X = Historical dataset 
𝐗𝒗𝒂𝒍 = Validation dataset 
𝐗𝒕𝒓𝒂𝒊𝒏 = Training dataset 
xj* = A subset of the j-th column vector of X 
Y = Historical output dataset  
y~ N (0, Σ) = y normally distributed with zero mean and Σ covariance matrix 
ydes = Desired quality target 
 
 
Σtot = Covariance of the total uncertainty 
τwet = Wet massing time 
υ = Degree of freedom for a Wishart or Inverse Wishart distribution 
ϕs = Infravoid fraction 
𝐱 ∊ 𝛘 = The vector x is in a “sweet spot” of the overlapping mean responses 
approach 
 
Acronyms 
API = Active Pharmaceutical Ingredient 
AR = Acceptable Range 
CMC = Chemistry, Manufacturing and Control 
CPP = Critical Process Parameter 
CQA = Critical Quality Attribute 
DOE = Design Of Experiment 
DS = Design Space 
EMA = European Medicine Agency 
FDA = Food and Drug Administration 
GMP = Good Manufacturing Practice 
ICH = International Conference on Harmonisation of technical 
requirements for registration of pharmaceuticals for human use 
ISPE = International Society for Pharmaceutical Engineering 
MCMC = Markov Chain Monte Carlo 
NIR = Near Infra-Red 
OMR = Overlapping Mean Responses 
PAT = Process Analytical Technology 
PAR = Proven Acceptable Range 
PCA = Principal Components Analysis 
PDF = Probability density function 
PLS = Partial Least Square 
PSE = Process System Engineering 
PPD = Posterior Predictive Distribution 
PQLI = Product Quality Lifecycle Implementation 
PQS = Pharmaceutical Quality System 
QbD = Quality by Design 
QbT = Quality by Testing 
QTPP = Quality target Product Profile 
SNRdB = Signal to Noise Ratio [dB] 
 
 
Rpm = Revolutions Per Minute [1/min] 
 
 
  
 
 
 
 
 
  
 
Appendix 
Appendix A: Code 
In this appendix bits of the code written for this work are reported, This is the code to 
approximate and compute the Em as for step 5) of the methodology of chapter §4.3 
 
[LOAD1,ECMdec,LOAD2]=svd(sigma_X);% 
tested=diag(ECMdec); 
%Eigenvalue greater than one to test the approximation 
test=tested(m+1)> 0.95; 
if test==1 
    disp('first discarded eigenvalue = ');disp(tested(m+1)) 
    disp('not safe to approximate the covariance') 
    return 
end 
LOAD21=LOAD1(:,1:m);ECMdec2=ECMdec(1:m,1:m); 
LOAD22=LOAD2(1:m,:); 
f=@(S_X_approx) sum(sum(((sigma_X))-(LOAD21*S_X_approx*LOAD22)).^2 );% 
S_X_approx=fminsearch(@(S_X_approx)f(S_X_approx),ECMdec2); 
S_TOT= sigma_S+sigma_M; 
S_M=pinv( pinv(S_X_approx) + pinv(S_TOT)); 
f=@(S_M) sum(sum((sigma_S+S_M)-(sigma_S+ inv(inv(S_X_approx)+ 
inv(sigma_S+S_M)))).^2 ); 
S_M=fminsearch(@(S_M)f(S_M),ECMdec2); 
sigma_M=diag(S_M).*eye(m); 
 
In this section, sigma_X is the assumed ΣΔX, sigma_S is the imposed covariance of the 
structural error and sigma_M is the error of measurement covariance. Both quantity are set to 
the identity matrix by default. 
In the following section a candidate for the measurement error covariance is generated from an 
Inverse Wishart distribution and its probability is assessed with the function 
“full_conditional_sigma_M” reported in the next page.  
 
if t ==1 
    f0 = m ; 
    if size(sigma_M)~=1 
        sigma_M=Spd_Mat(sigma_M); 
    end 
    sigma_M_new = iwishrnd(sigma_M,f0); 
else 
    if size(Gn_M_inv)~= 1 
       Gn_M_inv=Spd_Mat(Gn_M_inv); 
    end 
    sigma_M_new = iwishrnd(Gn_M_inv.*0.2,fn_M); 
end 
 
 
         
[pdf_sigma_M_new,fn_M_new,Gn_M_inv_new] = full_conditional_sigma_M 
(X,Y,sigma_M_new,theta,sigma_S) ; % full conditional of the proposal 
sigma 
[pdf_sigma_M,fn_M,Gn_M_inv] = 
full_conditional_sigma_M(X,Y,sigma_M,theta,sigma_S); % full conditional 
of sigma 
r_sigma_M = min (pdf_sigma_M_new/pdf_sigma_M,1); 
u_sigma_M = rand; % Seed from U(0,1)                                                                            
         
if u_sigma_M < r_sigma_M 
   sigma_M = sigma_M_new; 
   sigma_M_posterior_samples(:,:,t) = sigma_M; 
 pdf_sigma_M_posterior_samples =            
[pdf_sigma_M_posterior_samples,pdf_sigma_M_new]; 
   acceptance_rate_M = [acceptance_rate_M,1]; 
else 
   sigma_M_posterior_samples(:,:,t) = sigma_M; 
    pdf_sigma_M_posterior_samples = [pdf_sigma_M_posterior_samples,       
pdf_sigma_M]; 
end 
sigma_posterior_samples(:,:,t) = sigma_M+sigma_S; 
 
The function Spd_Mat assures that the input matrix is singular positive definite. 
Here the code for the full conditional distribution of the covariance of the measurement 
uncertainty is reported, using this function in the code reported above step 6.c) of the proposed 
methodology is concluded. 
 
function [full_cond_sigma_M,fn_M,Gn_M_inv] = 
full_conditional_sigma_M(X,Y,sigma_M,theta,sigma_S) 
%--------------------------------------------------------------------
marcoc 
% Full_conditional distribution of the covariance of the measurement 
% uncertainty 
% 
%                             Marco Cattaldo 
% 
% 
% CAPE-Lab - University of Padova (Italy) 
% 
%-----------------------------------------------------------------------
--- 
  
% Dimensions 
  
[m,m] = size (sigma_M); % dimension of the covariance of the residuals 
[n,k] = size(X);        % n = number of calibration samples; k = number 
of input variables 
[n,m] = size(Y);        % n = number of calibration samples; m = number 
of response variables 
  
theta = reshape(theta,k,m);  %reshape theta (k*m) 
  
% Initial values of the pdf parameters 
f0 = m ;   % to be tuned : it must be >= m 
G0_inv = f0.* eye(m,m); 
 
 
  
% Values of the parameters of the posterior pdf 
  
fn_M = f0+ n; 
ghi = (Y-X*theta)'*(Y-X*theta); 
  
%Y-Theta*X-Sigma_S=Sigma_M 
Gn_M_inv = G0_inv+ (Y-X*theta)'*(Y-X*theta)-(sigma_S); 
  
full_cond_sigma_M = 
det(Gn_M_inv)^(fn_M/2)/(det(sigma_M)^((fn_M+m+1)/2))*exp(-
1/2*trace(sigma_M*Gn_M_inv)); 
end 
 
 
  
 
 
 
 
  
Appendix B: Error in Variables model 
The error in variables model is a model to assess noisy measurement in the input and output 
calibration dataset. The Error in variables model consists in a minimization of every error term 
that is inserted in the model. While error in variable models have been approached mostly from 
the frequentist perspective, not much guidance is available on their Bayesian analysis (Lira and 
Grientschnig, 2017). 
The error in variables model was subject to investigation for a formulation of another 
methodology. In addition to the Methodology proposed in chapter §4.3 this one could process 
a nonlinear relation while accounting for the measurement error directly in the parameter 
selection step of the methodology without having to set up a MCMC for it. 
The Error in variables method can be formulated in a way similar to the classic measurement 
error shown in chapter §4.1, i.e.: 
𝐲 = (𝐗 − 𝐄𝑿)𝐁 + 𝐞𝐲,              (B.1) 
where y is the true output, A the true matrix of inputs, B the regression parameters and EA and 
ey are respectively the input measurement error and the output measurement error. 
Furthermore, while not assuming any knowledge on the y and X we can nevertheless assume 
that the error terms have zero mean and a covariance matrix, Σ, i.e.: 
൤
𝐞𝒚
𝐄𝑿
൨ = ൤
𝐞𝒚
vec 𝐄𝑿
൨ ~ ቂ𝟎𝟎, 𝛔
𝟐𝐐ቃ.             (B.2) 
In Equation (A2.2) vec (X) is the operation that vectorizes the matrix X [I×J] into a column 
vector [IJ×1], σ2 is the variance of unit weight and Q is the cofactor matrix. 
In the above example matrix Q can be written as: 
𝐐 = ൤
𝐐𝒚 𝐐𝑿𝒚
𝐐𝒚𝑿 𝐐𝑿
൨.              (B.3) 
The variance of unit weight and the cofactor matrix together form the variance/covariance 
matrix of the model, i.e.: 
𝚺 = 𝛔𝟐𝐐.              (B.4) 
At this point a model for the closure of this problem is needed. The model that has been 
considered is the Weighted Total Leas Square model. The weighted total least square problem 
can be stated as (van Huffel and Lemmerling, 2002): 
𝐏 = 𝐐ି𝟏 = ൤𝐏𝟏𝟏 𝐏𝟐𝟏𝐏𝟏𝟐 𝐏𝟐𝟐
൨,            (B.5) 
and 
 
 
ቐ
min [𝐞𝒚𝐓 vec(𝐄𝑿)𝐓] ൤
𝐏𝟏𝟏 𝐏𝟐𝟏
𝐏𝟏𝟐 𝐏𝟐𝟐
൨ ൤
𝐞𝒚
vec(𝐄𝑿)
൨
𝐲 = (𝐗 − 𝐄𝐗)𝐁 + 𝐞𝐲                                      
,              (B.6) 
Where the minimization of the first term is to be carried out in respect to the parameters B. 
This minimization is usually carried out by Lagrange multipliers and extensive details on its 
mathematical derivation can be found in van Huffel and Lemmerling, (2002) or Snow, (2012). 
This minimization yields: 
ቈ
𝐐𝟏 (𝐗 − 𝐄෨𝑿)
(𝐗 − 𝐄෨𝑿) 0
቉ ቂ𝛌𝐁ቃ = ൤
𝐲 −  𝐄෨𝑿𝐁
0
൨,              (B.7) 
𝐐𝟏 = 𝐐𝒚 + (𝐁⨂𝐈𝑰)𝐓𝐐𝑿(𝐁⨂𝐈𝑰),             (B.8) 
𝐄෨𝑿 = invec ((𝐐𝑿(𝐁⨂𝐈𝑰))𝛌,              (B.9) 
Where invec is the inverse of the vec operation of Equation (B.2) and forms a matrix with the 
original [I×J] dimensions, while ⊗ refers to the Kronecker product (Zehfuss, 1858). 
This formulation is true only when the cofactor matrices QyX and QXy are zero matrix. 
Equations B.7, B.8 and B.9 must be solved iteratively because the parameters B are present in 
both terms of the equation. Several algorithm are available to solve these iteration and a slight 
modification of “Algorithm 2” from Snow, (2012) was used in the investigation. 
The modified algorithm is reported in Table B.1 
Table B.1: the modified version of “Algorithm 2” from Snow, (2012) used in 
the incomplete methodology 
Step 1 Initialization: calculate B0 and set EX0= 0  
 𝐁𝟎 = ൫𝐗𝐓𝐐𝒚ିଵ𝐗 +  𝚺𝑩ିଵ൯
ିଵ
(𝐗𝐓𝐐𝒚ିଵ𝐲 + 𝚺𝑩ିଵ𝛍𝑩) 
(B.10) 
Step 2 while ||B(t)- B (t-1)|| < δ  
 𝐐𝟏௧ = 𝐐𝒚 + (𝐁௧ିଵ⨂𝐈ூ)୘𝐐𝑿(𝐁௧ିଵ⨂𝐈𝑰) (B.11) 
 𝚺௧ = ((𝐗 − 𝐄𝑿௧ିଵ)୘(𝐐𝟏௧ )ିଵ(𝐗 − 𝐄𝑿௧ିଵ) +  𝚺𝑩ିଵ)ିଵ (B.12) 
 𝐁௧ = 𝚺௧ × ((𝐗 − 𝐄𝑿௧ିଵ)𝐓(𝐐𝟏௧ )ିଵ(𝐲 − 𝐄𝑿௧ିଵ𝐁௧ିଵ) + 𝚺𝑩ିଵ𝛍𝑩) (B.13) 
 𝛌௧ = (𝐐𝟏௧ )ିଵ[(𝐲 − 𝐄𝑿௧ିଵ𝐁௧ିଵ) − (𝐗 − 𝐄𝑿௧ିଵ)𝐁௧] (B.14) 
 𝐞𝑿௧ = −(𝐐𝑿(𝐁௧⨂𝐈ூ))𝛌௧ (B.15) 
 𝐞𝒚௧ = 𝐐𝒚𝛌𝒕  (B.16) 
 𝐄𝑿௧ = invec (𝐞𝑿௧ ) (B.17) 
 
 
 
The modifications from the original algorithm are mainly in Equations (B.12) and (B.13) to 
include prior knowledge in the calculations of the parameters. 
In this methodology, still under investigation, the calculation of a prior for the Em as of step 5 
of the one proposed in chapter §4.3 is no longer necessary; furthermore, if data with different 
level of confidence are present their influence on the value of the parameters can be adjusted 
by using weighting within matrix Q. In the present investigation a variance of unit value of 1 
was used, such as Q = Σ. The methodology discussed in this appendix proposed to change the 
generation step for the parameters B to use the algorithm proposed in Table A2.1 to 
simultaneously describe the measurement error on X and y, while generating the parameters.  
The parameters are then assessed as per original methodology with a metropolis random walk 
algorithm and accepted with the criterion in the original methodology of Bano et al, (2018). 
The problem with this methodology and the area of current study is the acceptance of the error 
term EX; whether to use it to simulate a distribution for the error as part of the data pre-
processing and subtract it from the original data or using it to modify the X data matrix during 
the MCMC convergence process. The second approach has been tested and the results were 
found lacking. Having the error modelled explicitly by the methodology is surely an added 
benefit of the discussed methodology and as such this approach could be subject of further 
study along with the refinement of the methodology proposed in chapter §4.3 
A2.1 Code 
Following some of the code for the implementation of this method is reported; it is worth noting 
that this method as much of the error literature consider the output to be just a vector. A solution 
applied in this code is to iterate on each variable of the output matrix considering it a single 
vector. Starting from the hypothesis of independent response this can hold without problems, 
but other cases have to be investigated. 
 
function [full_cond_theta,Vxx] = 
full_conditional_theta_EIV(X,Y,theta,theta_mean,sigma,sigma_X) 
%--------------------------------------------------------------------marcoc 
% Full conditional distribution of the model parameters 
% 
%                           Marco Cattaldo 
% 
% CAPE-Lab - University of Padova (Italy) 
%-------------------------------------------------------------------------- 
  
% Dimensions 
  
 
 
[~,k] = size(X);     % n = number of calibration samples; k = number of 
input variables 
[~,m] = size(Y);     % n = number of calibration samples; m = number of 
response variables 
  
% Mean and covariance (to be tuned) 
  
u0 = reshape (theta_mean',k*m,1); 
c = 1e3;   %the higher the coefficient the lesser the impact of the priors 
V0 = kron(eye(m,m),c*eye(k,k)); 
[un,Vn,Vxx]=EIVMAPSnow2012V3(X,Y,u0,V0,sigma_X); 
Vn = Spd_Mat(Vn.*eye(k*m)); 
full_cond_theta = mvnpdf (theta,un,Vn);          %full conditional of theta 
  
end 
 
 
function [theta,stdth,Vxx]=EIVMAPSnow2012V3(X,Y,u0,V0,~) 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
%Simple algorithm without singular matrices, adapted from Snow, (2012) 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
[~,u]=size(Y); 
[~,m]=size(X); 
  
n=size(Y,1); 
PYY=kron(eye(u),eye(n)); 
PXX=kron((eye(m)),eye(n)); 
X=[ones(n,1),X]; 
  
[~,m]=size(X); 
PXX=[zeros(n,n*m-n);PXX]; 
PXX=[zeros(n*m,n),PXX]; 
QXX=pinv(PXX); 
QYY=pinv(PYY); 
sigma1=pinv(V0); 
sigma_t=zeros([m,m,u]); 
for i=1:u 
    h=i-1; 
 
 
    sigma_t(2:m,2:m,i)=sigma1(h*(m-1)+1:i*(m-1),h*(m-1)+1:i*(m-1)); 
end 
mean1=reshape(u0,m-1,u); 
mean_t=[ones(1,u);mean1]; 
theta=[]; 
for i=1:u 
    h=i-1; 
    
theta(:,i)=pinv(X'*PYY(h*n+1:i*n,h*n+1:i*n)*X)*(X'*PYY(h*n+1:i*n,h*n+1:i*n)
*Y(:,i)); 
end 
% % % % INITIALIZATION 
controlTH=1; 
thit=0; 
Vxx=zeros(n,m); 
stdth1=zeros([m,m,u*u]); 
% tic 
  
while controlTH>=5e-7  
    prevtheta=theta; 
    for i=1:u 
        h=i-1; 
         
        %save iteration i-1 
        thit=thit+1; 
        Xi=X-Vxx; 
        
Q1=QYY(h*n+1:i*n,h*n+1:i*n)+kron(prevtheta(:,i),eye(n))'*QXX*kron(prevtheta
(:,i),eye(n)); 
        Q1=pinv(Q1); 
        stdth1(:,:,i*i)=pinv((Xi)'*(Q1)*(Xi)+(sigma_t(:,:,i))); 
        stdth1(:,:,i*i)=(stdth1(:,:,i*i)+stdth1(:,:,i*i)')./2; 
        theta(:,i)=(stdth1(:,:,i*i)*((Xi)'*(Q1)*((Y(:,i)-           
Vxx*prevtheta(:,i)))+ (sigma_t(:,:,i))*mean_t(:,i))); 
        lambda(:,i)=(Q1)*((Y(:,i)-Vxx*prevtheta(:,i))-(Xi*theta(:,i))); 
        V(:,i)=(-QXX*kron(theta(:,i),eye(n)))*lambda(:,i); 
         
    end 
 
 
    Vx=sum(V,2); 
    Vxx=reshape(Vx,n,m); 
    controlTH=norm(prevtheta-theta,2) ;%%break condition 
    if thit>=30 
        controlTH=0; 
    end 
     
end 
theta=reshape(theta(2:end,:),u*m-u,1); 
Vxx=Vxx(:,2:end); 
  
for H=1:u 
    VAR{H}=matlab.lang.makeValidName(num2str(H))    ; 
    stdth2.(VAR{H})=[]; 
    h=H-1; 
    for K=1:u 
        k=K-1; 
        stdth2.(VAR{H})=[stdth2.(VAR{H}) ; stdth1(2:end,2:end,h*K+1+k)]; 
    end 
end 
stdth=[]; 
for i=1:u 
    stdth=[stdth,stdth2.(VAR{i})]; 
end 
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